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Abstract 
Hsin-Yuan Cheng: Regulation of the pulmonary vasculature by lysophospholipase D 
autotaxin - lysophosphatidic acid signaling 
(Under the direction of Dr. Susan S. Smyth) 
 
Lysophosphatidic acid (LPA) is a bioactive lipid molecule present at physiologically 
relevant levels in serum that acts by binding to a family of G-protein coupled receptors. 
Receptor active LPA is produced by the plasma lysophospholipase D enzyme 
autotaxin/lysoPLD. To define a role for LPA in the pulmonary vasculature, we examined 
the effect of reduced and elevated circulating LPA in a model of hypoxia-induced 
pulmonary vasoreactivity. We report that mice carrying one normal and one null allele of 
the gene encoding autotaxin/lysoPLD (Enpp2+/-), which have ~ half of plasma LPA, are 
hyper-reactive to hypoxia-induce vasoconstriction and remodeling as evidenced by the 
development of higher right ventricular systolic pressures, greater decline in peak flow 
velocity across the pulmonary valve, and a higher percentage of muscularized arteries at 
three weeks after exposure to hypoxia. Mice overexpressing human Enpp2 transgene 
(Enpp2-Tg) may be moderately protected from hypoxia-induced pulmonary hypertension 
with less reduction in peak flow velocity across the pulmonary valve after hypoxia 
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exposure.  
Because LPA1 and LPA2 receptors are highly expressed in the cardiovascular 
system and therefore are candidate receptors to mediate the effects of LPA, we examined 
the pulmonary vasculature of mice lacking LPA 1 and LPA2 (LPA1-/-2-/-). With age, 
LPA1-/-2-/- mice displayed elevations in right ventricular systolic pressure and developed 
right ventricular hypertrophy. No differences in pulmonary oxygen saturation, hematocrit, 
vascular permeability, platelet function, or blood coagulation were observed in LPA1-/-2-/- 
mice. LPA1-/-2-/- mice had a two-fold decline in peak flow velocity across the pulmonary 
valve after hypoxia versus wild-type controls, and increased muscularization of the 
pulmonary arterioles following hypoxia. Taken together, our results suggest that 
circulating LPA regulates pulmonary vascular pressure by effects on LPA1 and LPA2 
receptors.  
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Chapter 1 
Introduction: Pulmonary development and hypertension 
 
Lung development 
The stages of lung development  
    At around 4-6 week gestation in human and embryonic day 10 (E10) in mice, 
the development of the lung starts, and continues after birth until completed at ~7 
years in human and postnatal day 30 (P30) in mice 1. Lung development is divided 
into 4 stages- pseudoglandular, canalicular, saccular, and alveolar stages 1.   
    The pseudoglandular stage takes place at ~7-16 week gestation in human and 
~ E10-16.5 in mice. The development of the lung arises from the laryngotracheal 
groove, as it forms two parts, the larynx and the trachea. The progenitor cells at 
the distal part of the primitive trachea give rise to the left and right main-stem 
bronchi 1,2. Elongation and branching at the end of the bronchi repeat to form 
specific lobar, segmental, and lobular branches. The branching process continues 
into the canalicular stage, which takes place at 16-24 week gestation in human and 
~ E16.5-17.5 in mice 3. All the major lung elements except alveoli are formed, 
vascularization occurs, and the lumen of the bronchi expands during the 
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canalicular stage. In the saccular stage, 24-36 week gestation in human and 
E17.5-P5 in mice, the terminal saccules expand, and the specific respiratory 
epithelial cells appear, including type I pneumocytes for gas exchange, and type II 
pneumocytes for pulmonary surfactant secretion. The basal membranes of the type 
I pneumocytes and the endothelial cells of the capillary contact to form the 
blood-air barrier to exchange gas 1,2,4. The final stage is the alveolarization, which 
occurs after birth (birth to 7 years in human and P5-30 in mice). Alveolarization 
involves the septation of large primary saccules into smaller air space by the 
inward protrusion from the wall of the saccules to increase alveolar surface area 
for efficient gas exchange 3,5.  
    Alveolarization and angiogenesis tightly associate and coordinate with each 
other. Capillary vessels flank on one side of the invagitating septae. Later, fusion 
of the septae and septal capillaries form alveolar walls composed of pneumocytes 
and endothelial layers to allow gas exchange. The completion of alveolarization 
requires the spreading of the vasculature 6,7. Anti-angiogenesis agents prevent 
alveolarization in rats 8. 
    Factors affecting lung development include premature birth, hypoxia, early 
corticosteroid exposure, abnormal regulation/signaling of growth factors (PDGF, 
FGF, VEGF, TGF-β, and Wnt), and injury of the pulmonary capillaries 1,9,10.        
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Molecular aspects of alveolarization  
    Proper microvascular growth is required for alveolarization, and inhibition of 
angiogenesis results in incomplete alveolarization. Studies have shown the 
expression levels of angiogenetic markers VEGF/VEGFR2, Ang-1, Ang-2, and 
Tie-2 are up-regulated, and PlGF/VEGFR1 is at constant level to promote 
pulmonary microvascular growth during alveolarization in neonatal mouse lung. 
In the adult mouse lung, PlGF is down-regulated and VEGFR1 is up-regulated to 
stop angiogenesis, and VEGF/VEGFR2,, Ang-1, Ang-2 and Tie-2 are at relatively 
high levels for maintenance of the pulmonary microvasculature 11. Inhibition of 
angiogenetic molecules often leads to impaired alveolarization. For example, 
depleting platelet endothelial cell adhesion molecule 1 (PECAM-1) in rats by 
injecting anti-PECAM-1 antibody after birth results in incomplete alveolar 
septation in the lung. PECAM-1-null mice also present disruptive pulmonary 
structure and enlarged alveolar space which is evident as early as P1 12.      
    Transforming growth factor beta (TGF-β) is one of the most studied 
signaling molecules in lung development. TGF-β signals by binding of TGF-β 
type II receptor, which then recruits and phosphorylates the type I receptor. The 
phosphorylated type I receptor in turn phosphorylates the downstream 
receptor-regulated effectors, R-SMADs. The activated R-SMAD binds to the 
4 
 
common-mediator SMAD (co-SMAD) and the SMAD complex translocates to the 
nucleus to regulate transcription. The most common R-SMADs are SMAD 2 and 
3. There are also inhibitory SMADs (I-SMADs) to block the activation of 
R-SMADs. In general, the TGF-β signaling is anti-proliferative and induces 
differentiation and apoptosis 1,13.    
     Compiling evidences have shown that TGF-β is a negative regulator of 
alveolarization and lung development. Overexpression of TGF-β in the lungs of 
neonatal mice and rats both leads to impaired alveolar development 14,15. 
TGF-β–null mice die either before or shortly after birth with severe inflammation 
in the hearts and lungs 16. Neonatal mice expressing a dominant-negative form of 
TGF-β receptor II are resistant to hypoxia-induced pulmonary vascular 
remodeling and disruption of alveolarization 17. Neonatal mice deficient of Thy-1, 
an inhibitor of TGF-β signaling, show exacerbated responses to hypoxia-induced 
disruption of alveolar septation. Administration of TGF-β neutralizing antibody to 
the Thy-1-/- mice is able to rescue the impaired alveolarization 18. Together, these 
data suggest that excessive TGF-β signaling has adverse effects on lung 
development, especially the alveolarization stage.  
    One the contrary, other studies suggested an alternative relationship between 
TGF-β signaling and lung development. Mice deficient of SMAD3, one of the 
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major R-SMAD, display enlarged alveolar space shortly after birth. The disruption 
of pulmonary structure progresses in an age-dependent manner, as the 
enlargement of alveoli becomes more evident in older mice 19,20.  
One explanation for the dual effects of TGF-β signaling on alveolarization 
could be that it is dynamically regulated during lung development. In fact, the 
expression levels of key molecules in the TGF-β signaling pathway are found to 
vary significantly in mouse lungs throughout the course of lung development 21.      
 
Pulmonary arterial hypertension  
Clinical aspects of pulmonary arterial hypertension 
The World Health Organization classification of pulmonary hypertension (PH) 
defines 5 groups: pulmonary arterial hypertension (PAH), PH with left heart 
disease, PH associated with lung diseases and/or hypoxemia, PH resulting from 
chronic thrombotic and/or embolic diseases, and miscellaneous PH 22. PAH, also 
referred as primary PH, is the focus of this introductory section. The other 4 
groups are categorized as the secondary PH.  
PAH is characterized by sustained elevation of pulmonary arterial pressure 
(PAP) and pulmonary vascular resistance (PVR). In humans, PAH is defined by a 
mean PAP over 25 mmHg at rest or 30 mmHg with exercise, a pulmonary arterial 
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wedge pressure of 15 mmHg or less, and a PVR of 3 or more Wood units (240 
dyn.sec.cm-5) 22,23. The prevalence of PAH is estimated at ~50,000 to 100,000 in 
the United States 22,24. PAH is a progressive and devastating disease with a median 
survival after diagnosis of 2.8 years 25. The symptoms of PAH are generally 
nonspecific, including breathlessness, fatigue, angina, syncope, cough, fluid 
retention, and exercise-induced nausea and vomiting, and may delay the diagnosis 
26
. Treatments of PAH include lifestyle modifications, conventional treatments, 
such as diuretics, oxygen supplementation, anticoagulation agents, and 
disease-specific treatments, which will be discussed in more detail below 27. Yet, 
the efficacy of current treatments remains unsatisfied with relatively small groups 
of patients responding effectively to the treatments 28-30.  
 
Molecular aspects of pulmonary arterial hypertension 
The pulmonary circulation is highly-compliant with high blood flow, low 
pressure, and low resistance to adapt large changes in blood flow with little 
alteration of pressure.  In particular, contraction of pulmonary vascular SMCs is 
tightly regulated by a balance between vasodilators and vasoconstrictors.  When 
the balance fails, pulmonary vascular resistance and arterial pressure elevate, and 
PAH ensues with remodeling of the pulmonary arteries 22,27,29. The pulmonary 
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endothelial cells are the major contributors for the vasodilators and vasoconstrictors, 
and therefore endothelial cell dysfunction which leads to inadequate secretion of 
these factors may be an initial cause of PAH 29,31. Three major vasoconstricting and 
vadodilatory pathways in the pulmonary vasculature are the nitric oxide, endothelin, 
and prostacyclin pathways, which are discussed in more detail below. 
 
Nitric Oxide 
In the pulmonary vasculature, nitric oxide (NO) is a potent vasodilator 
produced by endothelial NO synthase (eNOS) from L-arginine in vascular 
endothelial cells. The released NO targets vascular SMCs to stimulate cyclic GMP 
(cGMP) production, which decreases cytosolic calcium levels and promotes 
muscular relaxation. The termination of NO signaling occurs by hydrolysis of 
cGMP by the cGMP specific phosphodiesterase type 5A (PDE5A) 27. NO also acts 
on endothelial cells to inhibit the production of endothelin, a vasoconstrictive factor 
27
. 
     eNOS is expressed predominantly in the vascular endothelial cells, as well as 
airway epithelium and certain other cell types, and is the major contributor for NO 
synthesis in the pulmonary circulation 32,33. Previous studies reveal a strong link 
between eNOS activity and the development of hypertension. A reduction in eNOS 
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expression is found in the lungs of primary PAH patients. Pulmonary vascular 
endothelial cells from severe cases showed little or no eNOS expression when 
compared to those from normal subjects 34. Mice genetically deficient of eNOS 
develop systemic hypertension 35, while mice overexpressing eNOS display 
systemic hypotension 36.  eNOS-/- mice are hyperresponsive to hypoxia and 
develop exaggerated elevations in right ventricular systolic pressure and have a 
higher incidence to develop right ventricular hypertrophy 37,38. On the other hand, 
mice overexpressing eNOS are protected from hypoxia-induced PAH 36. Mild 
hypoxia exposure of neonatal eNOS-/- mice results in disrupted alveolarization and 
reduced vessel density in the lung. VEGRFII expression is lowered in hypoxic 
eNOS-/- mice, suggesting the NO signaling is required in normal lung septation 
through preservation of VEGFRII signaling 39. Therefore certain common 
mediators, such as eNOS, are required for regulation of pulmonary pressure and 
development.     
Multiple mechanisms have been shown to regulate eNOS activity. Various 
hormones and cytokines such as estradiol and VEGF stimulate eNOS intracellular 
translocation by elevating cytosolic calcium concentrations. Shear stress and 
isometric vessel contraction also modulate eNOS activity via phosphorylation of 
diverse G protein-coupled receptors 40,41. 
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Therapies that target the NO pathway in the PAH includes NO or nitrate donor 
supplements, PDE5A inhibition, and calcium channel blockade 23,27,29.  
 
Prostacyclin 
Prostacyclin is produced from arachidonic acid by cyclooxygenases (COX) 
and prostacyclin synthase in endothelial cells. COX-2 and prostacyclin synthase are 
thought to be the two major enzymes for prostacyclin production 27,42. On the other 
hand, COX-1 is responsible for producing thromboxane A2, a vasoconstrictor 42. 
Selective blockage of COX-2 leads to an imbalance between prostacyclin and 
thromboxane A2 43,44. Upon secretion and subsequent uptake by the prostacyclin 
receptor on SMCs, prostacyclin induces vasodilation by stimulating cyclic AMP 
(cAMP) production to trigger cAMP-PKA-  dependent SMC relaxation 27,29.  
Mice deficient of COX-2 show exacerbated PAH comparing to WT controls in 
the setting of hypobaric-hypoxia 45. Prostacyclin receptor knockout mice also show 
similar responses to hypobaric-hypoxia- induced PAH 46. Prostacyclin levels and 
prostacyclin synthase activity are reduced in PAH patients 47. Clinically, 
intravenous injection or inhalation of prostacyclin and its analogous have been used 
to treat PAH 27,29.  
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Endothelin 
Endothelin (ET), produced predominantly by endothelin-converting enzymes 
(ECE) in the endothelial cells, is a 21-amino acid peptide. Three isoforms of ETs 
have been identified, ET-1, ET-2, and ET-3. ET-1 is the major isoform which, upon 
secretion, acts on neighboring SMCs in a paracrine manner to induce SMC 
constriction and proliferation 27. The receptors for ET are G-protein couple 
receptors, ETA and ETB. ETA is expressed predominantly in SMCs, and ETB 
expresses in both SMCs and endothelial cells. Both ETA and ETB mediate 
vasoconstriction and proliferation of the SMCs. However, the endothelial ETB 
serves as a vasodilatory receptor to stimulate the release of NO and prostacyclin, 
two vasodilators. Endothelial ETB is also responsible for uptake and hence 
clearance of ET 27,29. ET release is regulated by gene expression and peptide 
synthesis because endothelial cells do not store it. The most potent factor to regulate 
the synthesis of ET is blood flow. Increases in blood flow trigger vasodilation by 
activating shear stress receptors on endothelial cells to produce and secrete NO and 
prostacyclin. These vasodilators in turn inhibit ECE and ET synthesis 27,48.  
Acting as the most potent vasoconstrictors in the pulmonary vasculature, ET 
expression is found to be up-regulated in the lung of PAH patients 49. Plasma ET-1 
levels correlate with the severity of PAH 50,51. Knockout and transgenic animal 
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models have revealed roles for the ET pathway in embryonic development, but not 
much information is available on the development of PAH 52,53. For example, 
ET-1-/- mice die of respiratory failure likely due to mechanical obstruction of 
craniofacial abnormalities at birth. ET-1+/- mice show mild but significant elevation 
of systemic blood pressure 54. ET-1 transgenic mice display fibrosis in multiple 
tissues including lung and kidney, but otherwise normal right ventricular systolic 
pressures 55,56. Interestingly, Han et al. reported in an abstract that knocking out 
ET-2, a less studied endothelin isoform, results in impaired alveolarization and RV 
hypertrophy in mice 151. Treatments of PAH targeting the ET pathway are 
endothelin receptor antagonists, such as the dual (ETA and ETB) receptor antagonist 
bosentan, and selective ETA antagonists sitaxsentan and ambrisentan. 29.  
 
Bone morphogenetic protein 
    In the classic view of PAH, SMCs contract and proliferate in response to the 
sustained imbalance of vasoconstrictors/vasodilators secreted form endothelial 
cells. However, compiling evidences indicate SMC dysfunction could also be a 
direct cause of PAH. One example is the bone morphogenetic protein (BMP) 
pathway. BMP is a negative regulator of SMC growth. Loss-of-function mutations 
of BMP receptor II (BMPRII) are found in high incidences in PAH patients 
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(50-60% of familial PAH patients, and 10-20% of idiopathic PAH patients) 23,57-59. 
Although the loss of BMPRII signaling could induce endothelial apoptosis and lead 
to PAH 60, studies have shown that it also results in proliferation of cultured 
pulmonary arterial SMCs 57,61. PPARγ is thought to be the downstream effector to 
mediate the anti-proliferative response of BMP in the SMCs, and deletion of PPARγ 
in mice leads to PAH with increased right ventricular systolic pressure (RVSP), RV 
hypertrophy, and pulmonary vascular remodeling 57.  
  
Chapter 2 
Introduction: Autotoxin/LysoPLD and LPA signaling 
 
Lysophosphatidic acid 
    Lysophospholipids are derivatives of glycero- and sphingophospholipids 
lacking one O-acyl chain. Lysophosphatidic acid (1-acyl 2-hydroxyl glycerol 
3-phosphate, LPA) and sphingosine-1-phosphate (S1P) are two major bioactive 
lysophospholipids with wide-ranging biological effects including cell proliferation, 
apoptosis, adhesion., migration, and invasion 62. LPA circulates in blood, and is 
bound to plasma proteins, such as albumin, and found in lipoprotein particles. 
Most of the effects of LPA are mediated by binding to G-protein coupled receptors, 
which will be discussed in detail below.     
 
The production and degradation of LPA 
    Physiological relevant levels of LPA can be detected in the blood. LPA is 
present in human plasma at ~ 0.1 µM, and are ~ 10-fold higher in serum 63. The 
steady state of circulating LPA is balanced between opposing pathways of LPA 
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synthesis and degradation. A variety of pathways are proposed to be participated 
in de novo synthesis or through phospholipase-catalyzed hydrolysis of 
phospholipids to produce LPA. However, the primary route of circulating LPA 
production involves hydrolysis of lysophosphatidylcholine (LPC) by the secreted 
enzyme autotaxin/lysophospholipase D (lysoPLD) 64. Autotaxin/lysoPLD is a 
member of the ectonucleotide pyrophosphatase/phosphodiesterase (Enpp) family, 
designated Enpp2, with a unique ability to hydrolyze LPC.  
    Homozygous deletion of Enpp2 in mice results in embryonic lethality. 
Enpp2-/- mice die approximately around E9.5~E10.5 due to vascular defects in 
yolk sac and embryo, and failure of vessel maturation 65,66. Heterozygous Enpp2 
mice (Enpp2+/-) are viable without showing obvious developmental defect and have 
approximately half of normal circulating autotoxin/lysoPLD and LPA levels. Our 
group recently found that Enpp2+/- mice were prone to thrombosis 63. On the 
contrary, mice transgenically overexpressing autotaxin/lysoPLD (Enpp2-Tg) with 
elevated circulating LPA level, have bleeding diathesis and attenuated thrombus 
formation. Exogenous administration of LPA elevates circulating LPA level and 
recapitulates the bleeding phenotype of Enpp2-Tg mice. The phenotypes could be 
due to accumulation of autotaxin/lysoPLD in aggregated platelets and platelet-rich 
thrombus, and binding to activated platelets in a β3 integrin-dependent manner 63.  
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Inactivation of LPA in the circulation likely involves activities of the lipid 
phosphate phosphatase (LPP) family of cell surface integral membrane proteins 67. 
LPP activity, protein and mRNA can be detected in various cell types including 
platelets, leukocytes, vascular endothelial cells and SMCs 68,69. Inactivation of 
LPP2, one of the three mammalian LPP genes in mice, has been reported to produce 
no phenotype although circulating LPA levels have not been measured in these 
animals 70. A recent report also states no remarkable phenotypes when inactivating 
LPP1 in mice 71. By contrast, inactivation of the LPP3 gene results in early 
embryonic lethality but LPP3 heterozygotes are viable 72. The production, 
degradation, and signaling of LPA is illustrated in figure 2.1. 
 
Signaling of LPA 
LPA acts through binding to a family of G protein-coupled receptors (GPCRs). 
To date, there are at least five bona fide LPA receptors, LPA1-5 62,73, with at least 
three more potential ones (LPA 6 – 8)74,75. Evidences also show that LPA may serve 
as an endogenous activator of PPARγ 76,77. LPA1-3 belong to the original Edg class 
receptors, whereas most of the more recently identified LPA receptors show greater 
sequence identity with purinergic receptors. LPA receptors 1 – 5 are expressed 
ubiquitously in most mammalian tissues. Bound to circulating LPA, these LPA 
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receptors couple to multiple heterotrimeric G proteins (Gi/o, Gq/11/14, Gs, and G12/13) 
and initiate various signal transduction pathways 78. Figure 2.2 shows a schematic 
network of LPA signaling through receptors, G proteins, and downstream effectors.  
In vitro studies in cell lines reveal that LPA receptors share certain function 
redundancy as well as specificity 62,79,80. Several LPA receptors deleted mice were 
reported. LPA1-/- mice show craniofacial dysmorphism, reduced size, a small 
incidence of perinatal frontal hematoma, increased apoptosis in sciatic nerve 
Schwann cells, and 50% neonatal lethality 81. Deletion of Lpa3 results in 
implantation defects 82,83. LPA3-/- female mice produced significantly reduced litter 
size due to delayed implantation and altered embryo spacing 83.  Lpa2-deficient 
and Lpa4-deficent mice display no obvious phenotypes 84,85, while cells from 
Lpa4-deficient mice display enhanced migration in response to LPA85. Mice 
deficient of both Lpa1 and Lpa2 present similar abnormities as knocking out Lpa1 
alone with an increased incidence of frontal hematoma and lethality 78,84. 
 
Effects of LPA on vascular smooth muscle cells 
Phenotypic modulation of vascular SMCs occurs in response to vascular 
injury or consistent vascular pressure elevation 86,87. Phenotypic modulation of 
SMCs involves their conversion from a normally quiescent, differentiated, 
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contractile state to a dedifferentiated state in which the cells proliferate, migrate 
and synthesize matrix proteins.  
Isolated SMCs from human and rodent species can be stimulated to 
dedifferentiate, proliferate, and migrate by serum, and LPA has been proposed as 
one of the factors present in serum that may promote phenotypic modulation of 
vascular SMCs 88-90. Indeed, isolated vascular SMCs respond to LPA by 
proliferating and migrating 91-93. Although the specific LPA receptors and their 
signaling systems involved in SMC responses are not known, prominent pathways 
that are activated by LPA include Rho GTPases and extracellular-signal regulated 
kinase (ERK). LPA also regulates expression of early growth response-factor-1, a 
transcription factor, which stimulates expression of pro-inflammatory cytokines, 
adhesion molecules, growth factors, and coagulation factors 94. LPA can promote 
tissue factor expression by SMCs 95, which may be a key component of the 
vascular wall involved in triggering thrombus formation 96. Exogenous 
administration of LPA to animals elicits responses consistent with it serving as an 
endogenous mediator of vascular cell function. For example, intravenous injection 
of LPA elevates arterial blood pressure in rats 97 and local application causes 
cerebral vasoconstriction in pigs 98. Moreover, local infusion of LPA in the rat 
common carotid artery induces vascular remodeling by stimulating neointimal 
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formation 99. A similar response was observed in mice and was proposed to be 
mediated by PPARγ 77.       
The finding that LPA is capable of eliciting the development of intimal 
hyperplasia, which involves phenotypic modulation of SMCs, suggests that it may 
normally regulate SMCs, and our group have observed differences in the 
development of neointimal hyperplasia in mice lacking LPA1 receptor and in mice 
lacking both LPA1 and LPA2 in response to vascular injuries 100. In the same study, 
we also established that neither LPA1 nor LPA2 was required for LPA to elicit a 
transient increase in blood pressure following intravenous administration of LPA 
to mice. Mice lacking both LPA1 and LPA2 responded similarly as wild-type (WT) 
mice in systemic blood pressure elevations in response to LPA infusion.    
 
Effects of LPA on endothelial cells 
LPA promotes endothelial cell migration through mechanisms that involve 
regulation of the actin cytoskeleton and the extracellular matrix 101,102. LPA has 
been variably associated with increasing or decreasing endothelial barrier function 
but the inconsistencies between these sets of observations may arise from 
differences between the types of endothelial cells, the source of LPA, and the 
experimental approached used in these studies 103. For example, several 
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investigators report that LPA stabilizes endothelial barrier function 104, decreases 
endothelial permeability 105, and increases endothelial resistance 106, whereas 
others have found that LPA promotes the loss of vascular integrity and decreases 
trans-endothelial resistance by preventing tight junction formation 107,108. In lung 
injury models, vascular leak is mediated by the LPA1 receptor 109. In cell culture 
systems, LPA triggers an inflammatory response in endothelial cells that includes 
up-regulation of expression of leukocyte chemoattractants 110 and adhesion 
receptors 111 in an LPA1 and LPA3- dependent manner 110 112. These responses can 
regulate endothelial–leukocyte interactions by promoting monocyte binding to 
endothelial cells 111. LPA also activates eNOS in endothelial cells 113 and may 
thereby regulate endothelial tone. 
 
   Effects of LPA in the lung 
    As discussed above, LPA has been shown to regulate contraction of other 
types of SMCs, such as aortic SMCs. In tracheal smooth muscle rings from both 
rabbits and cats, LPA alone does not cause contraction, but enhances the 
contractile response by methacholine 114. This study was one of the first to suggest 
LPA’s role in asthma, since asthmatic airways are hyperresponsive to contractile 
stimuli. The enhancement of contractility by LPA was not altered by removal of 
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epithelial cells, suggesting that LPA acts directly on SMCs, and the effect is 
independent of epithelial-derived mediators. The activation of Gi, Gq, and Rho 
were required for the effect 115,116. LPA also strongly stimulate the proliferation of 
airway SMCs, and the mitogenic effect of LPA is completely blocked by pertussis 
toxin 117,118. 
    Airway epithelium is the first site of contact for inhaled particles and hence 
functions as a barrier to environmental stimuli. Recently He and colleagues 
reported LPA enhances the barrier integrity of pulmonary epithelial cells, and 
protects endotoxin-induced epithelial barrier disruption and lung injury. The 
effects of LPA are through PKCδ and PKCζ mediated E-cadherin accumulation at 
the cell-cell junctions. Their data suggest a protective role of LPA in airway 
inflammation and remodeling 119,120. However, other studies showed pulmonary 
epithelial cells undergo rapid proliferation in response to LPA, which results in a 
transient decrease in inflammatory cytokines followed by an up-regulation of 
these cytokines that could lead to increased inflammation 121,122.  
    Pulmonary fibrosis begins as fibroblasts migrate into and fill up the airspace. 
The study by Tager and colleagues identified LPA as a key chemoattractant for 
lung fibroblasts after injury. LPA level increased in bronchoalveolar lavage fluid 
following bleomycin-induced lung injury in mice. Mice genetically deficient of 
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LPA1 were protected from fibrosis and mortality in this model. The absence of 
LPA1 led to reduced fibroblast recruitment and increased endothelial permeability, 
two responses that may be excessive in injuries that lead to fibrosis. In idiopathic 
pulmonary fibrosis patients, LPA levels in bronchoalveolar lavage fluid were also 
found to be increased.  LPA1 antagonist markedly reduced responses of 
fibroblasts to the chemotactic activity of this fluid. Therefore LPA1 was identified 
as the receptor mediating LPA’s chemoattractant effect in pulmonary fibrosis 
109,123
. 
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Chapter 3 
Autotaxin/lysoPLD level regulates susceptibility to hypoxia-induced 
pulmonary hypertension in mice 
 
Introduction 
Arterial SMCs play an important role in vessel contraction and relaxation and, 
following systemic vascular injury, can undergo phenotypic modulation to a 
proliferative/synthetic state that likely contributes to the development of 
atherosclerosis and restenosis 100.  In the highly-compliant pulmonary circulation, 
which is characterized by high blood flow, low pressure, and low resistance, 
adaptations accommodate large changes in blood flow with little alteration of 
pressure.  In particular, contraction of pulmonary vascular SMCs is tightly 
regulated by a balance between vasodilators and vasoconstrictors.  When the 
balance fails, pulmonary arterial hypertension (PAH) ensues, with elevated 
pulmonary vascular resistance and sustained high pulmonary arterial pressure 
22,27,29
.  The main characteristics of PAH are vasoconstriction and vascular 
remodeling, including pulmonary vascular SMC proliferation and hypertrophy.  
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Additionally, endothelial dysfunction and in-situ thrombosis can occur 22,24,29.   
Overtime, pressure overload of the right ventricle (RV) results in RV hypertrophy, 
dilatation, and dysfunction 22,124. In fact, PAH is the leading cause of RV 
hypertrophy and failure 125. Unfortunately, to date, very little is known about in 
initial establishment of PAH, making prevention and effective treatment 
challenging 28. 
LPA is a bioactive lipid molecule present at physiologically relevant levels in 
plasma and serum 126. The earliest evidence for biological activity of LPA came 
from studies demonstrating that it had pressor effects when administered to rats and 
guinea pigs97  LPA had been proposed to contribute to phenotypic modulation of 
culture vascular SMCs and appears to modulate arterial remodeling responses in 
carotid arteries of rodents.  LPA may also have important effects on endothelial 
cell function and endothelial barrier integrity 62,73,79. 
The predominant route for LPA production in blood involves hydrolysis of 
LPC by the secreted plasma protein autotoxin/lysoPLD 64. Autotaxin/lysoPLD is a 
member of the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) family 
and is designated ENPP2.  The loss of autotaxin/lysoPLD in mice as a 
consequence of Enpp2 gene deletion results in a much more striking phenotype 
than has been observed to date in any of the receptor knockout mice.  Enpp2-/- mice 
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die embryonically and display vascular defects and vessel maturation failure 65,66. 
Heterozygous Enpp2 mice (Enpp2+/-) exhibit no obvious developmental defect and 
have approximately half of normal circulating autotoxin/lysoPLD and LPA levels. 
Transgenic mice overexpressing human Enpp2 have increased plasma 
autotoxin/lysoPLD activity and LPA levels 63. These findings establish that 
autotoxin/lysoPLD plays an essential role in regulating circulating LPA levels in the 
blood and suggests that LPA may contribute to vascular development. 
While substantial evidence suggests a role for LPA in regulating phenotypic 
modulation of cultured vascular SMCs and systemic arterial remodeling in rodent 
models, nothing is known about the effects of LPA on the pulmonary vasculature. In 
this chapter, we examined the role of LPA in regulation of the pulmonary 
vasculature using mice in which the autotaxin/LPA signaling axis is altered. 
Chronic hypoxia is used extensively to induce experimental PAH in different 
animal species 36. Mice exposed to sustained low oxygen environment first respond 
by vasoconstriction in the lung, and later develop pulmonary arterial remodeling 
and increased pulmonary resistance.  SMC proliferation is one key characteristics 
of pulmonary vascular remodeling in response to sustained pressure elevation, and 
is usually assessed by increasing muscularized arterioles and thickening of the 
arteriolar wall. The sustained pressure elevation in the pulmonary vasculature in 
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turn elevates RV pressure and lowers the peak flow velocity across the pulmonary 
valve. The progression of pulmonary arterial hypertension in response to hypoxia is 
summarized in Figure 3.1. In this chapter, mice with decreased and elevated 
autotoxin/lysoPLD levels are subjected to hypoxia to induce experimental 
pulmonary hypertension. The development of PAH will be assessed by measuring 
RV systolic pressure, peak flow velocity across the pulmonary valve, and 
muscularization percentage of pulmonary arterioles. 
  
Materials and Methods 
Mice 
All procedures conformed to the recommendations of Guide for the Care and Use 
of Laboratory Animals (Department of Health, Education, and Welfare publication 
number NIH 78-23, 1996) and were approved by the Institutional Animal Care and 
Use Committee. Generation and characterization of Enpp2+/- and Enpp2-Tg were as 
previously described 66 63. The Enpp2+/- and Enpp2-Tg are back-crossed to FVB 
background. Mice were housed in cages with HEPA filtered air in rooms on 12-hour 
light cycles and fed Purina 5058 rodent chow ad libitum.  
Hypoxia model 
Mice were exposed to oxygen-poor air (hypoxia) at normal atmospheric pressure by 
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placement of their cages in a commercially available chamber (A-chamber, 
BioSpherix). The mice resided in the chamber for 24 hrs per day for 3 weeks to 
induce pulmonary hypertension and vascular remodeling, and were removed from 
the chamber only for cage, food, and water changes.  The hypoxic environment 
within the chamber was achieved by inflow of compressed nitrogen gas. The 
oxygen concentration (FIO2 = 0.10) was controlled by a commercially available 
oxygen controller (Proox model 110, BioSpherix).  Prior and after 3 weeks of 
hypoxia treatment, echocardiography was performed to evaluate the cardiac 
function. RV pressures measurements were performed in both normoxic and 
hypoxic groups. Mice were then euthanized, and organs were collected for 
histological, biochemical, and gene expression analysis.   
Echocardiography 
Transthoracic echocardiography was performed using a 30 MHz probe and the 
Vevo 770 Ultrasonograph (VisualSonics). Mice were lightly anesthetized with 0.8 
% isoflurane, maintaining heart rate at 400–500 beats/min. The hair was removed 
from the chest using a chemical hair remover (Nair®). The heart rate and body 
temperature were maintained and recorded. Two-dimensional parasternal long- and 
short-axis views were obtained. M-mode tracings were recorded and used to 
determine LV end-diastolic diameter (LVEDD) and LV end-systolic diameter 
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(LVESD). LV fractional shortening (FS) was calculated using the formula %FS = 
(LVEDD - LVESD) / (LVEDD). For determining the flow across the pulmonary 
valve, high short-axis view was obtained at the level of the right ventricular outflow 
tract and in which the pulmonary valve can be easily seen. The Doppler mode 
cursor was positioned at the end of the pulmonary valve to record the peak velocity 
across the pulmonary valve.  
RV pressure measurement 
Under anesthesia (inhaled isoflurane 1 – 3%), the mouse was fixed in a supine 
position with tape on a mouse pad that has imbedded EKG electrodes and surface 
mounted semi-conductor temperature sensor that distributes heat through surface 
mounted resistors. Rectal temperature was monitored. Under direct visualization of 
the trachea, an endotracheal tube was inserted and connected to a Harvard rodent 
volume-cycled ventilator (Model 645, Harvard Apparatus) via the Y-shaped 
connector. Ventilation was performed with a tidal volume of 200 µL and a 
respiratory rate of 150/min. Oxygen was provided to the inflow of the ventilator. 
The chest cavity was opened by an incision of the left fourth intercostal space. An 1 
French catheter (Millar Instruments) was quickly inserted into the RV and pressure 
traces was obtained by Chart 5 Pro (AD Instruments). The animal was euthanized 
while still under anesthesia, and organs were obtained for histology and RT-PCR 
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analysis. 
Real-time PCR 
Total RNA was extracted from tissues and primary cultured cells using Trizol 
(Invitrogen) following manufacturer’s instructions. cDNA was prepared with 
Multiscribe reverse-trasncriptase enzyme as per manufacturer’s directions 
(High-Capacity cDNA Archive Kit; Applied Biosystems). mRNA expression was 
measured by real-time quantitative PCR using TaqMan® gene expression assays 
(Applied Biosystems) in an ABI Prism® 7500 Fast Real-Time PCR System. 
Threshold cycles (CT) were determined by an in-program algorithm assigning a 
fluorescence baseline based on readings prior to exponential amplification. Fold 
change in expression was calculated using the 2-δδCT method. 18s ribosomal RNA 
was used as an endogenous control. 
Histology 
Mice were weighed, and hearts, lungs, livers, and kidneys were dissected, rinsed in 
PBS, and weighed. Hearts were cut in a cross section at the widest point. The top 
half of the heart was fixed with 4% paraformaldehyde and embedded in paraffin. 5 
µm sections of hearts and lungs were prepared with microtome. The sections were 
stained with hematoxylin and eosin (H&E) for examination of gross appearance, 
whereas Masson’s Trichrome, periodic acid-Schiff (PAS), counterstained with 
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hematoxylin (PAS-H), and van Gieson elastin staining was employed to facilitate 
quantification of fibrosis, cardiomyocyte size, and elastin content respectively. The 
muscularization percentage of small arterioles was quantified with lung sections 
immunostained with the biotinylated anti- α-smooth muscle actin antibody (Sigma). 
The dilution fold of the antibody was 1 to 100 in PBS. Small arterioles with 
diameters ranging in 15-100 µm were scored. Arterioles with no positive α-smooth 
muscle actin staining were characterized as non-muscularized, wrapped with 
0-75% positive staining as partially-muscularized, and >75% positive staining as 
fully-muscularized vessels. 50 arterioles in each section were counted.  
Statistics 
All results were expressed as mean ± SD. In vitro studies were repeated a minimum 
of 3 times, and results were analyzed by Student t test or ANOVA. Statistical 
significance within strains was determined using ANOVA with multiple pair-wise 
comparisons. Statistical analysis was performed using Sigma-STAT software 
version 3.5 (Systat Software Inc). A probability value of less than 0.05 was 
considered significant. 
     
    Results 
Reduction in autotaxin/lysoPLD promotes hypoxia-induced pulmonary 
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remodeling in mice   
LPA has been proposed to play a role in phenotypic modulation of cultured 
vascular SMCs and may regulate systemic arterial remodeling in experimental 
models.  However, nothing is known about the effects of LPA on the pulmonary 
vasculature.  To explore the role of LPA in the pulmonary vasculature, mice with 
reduced and elevated levels of the autotoxin/lysoPLD, the major LPA producing 
enzyme, were exposed to oxygen-poor air (hypoxia) for 3 weeks. In response to 
hypoxia, pulmonary vasoconstriction occurs and is followed by remodeling of the 
pulmonary vasculature. In wild-type (WT) mice, hypoxia results in an increase in 
pulmonary arterial pressure, which can be monitored by measuring right ventricular 
systolic pressure (RVSP) by insertion of a pressure catheter directly into the right 
ventricle.   Following hypoxia exposure (FiO2=0.1), an increase of RVSP occurs 
in WT mice (30.3 ± 2.3 mmHg; n =6) compared to RVSP in age-matched normoxic 
littermates (25.7 ± 2.1 mmHg; n =6) (Figure 3.2).  
   To determine if LPA contributes to pulmonary remodeling, we subjected 
mice with varying levels of LPA to hypoxia.  Inherited deficiency of 
autotaxin/lysoPLD (Enpp2-/-) in mice results in embryonic lethality by E10.5 due to 
vascular defects 65,66, heterozygous Enpp2+/- mice have reduce LPA levels, but are 
viable with no obvious vascular developmental abnormalities.  Likewise, Enpp2+/- 
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mice display similar RVSP (23.8 ±1.8 mmHg; n =5) under normoxic conditions as 
their WT littermates.  Following a 3-week exposure to hypoxia, Enpp2+/- mice 
developed higher RVSP (36.2 ± 5.2 mmHg; n=7) then did their WT littermates 
(30.3 ± 2.3 mmHg; n =6) (Figure 3.2). Although the difference of RVSP values was 
not statistically significant between hypoxic Enpp2+/- mice and WT littermates, we 
noticed that the difference of RVSP was significant between normoxic and hypoxic 
Enpp2+/- mice, while it was not statistically significant between normoxic and 
hypoxic WT groups. Therefore Enpp2+/- mice seemed to show greater reaction to 
hypoxia-induced RVSP elevation.     
The peak flow velocity across the pulmonary valve was measured by 
echocardiography as an indication of RV stroke volume before (baseline) and after 
3 weeks of treatments (normoxia or hypoxia). Peak flow velocity across the 
pulmonary valve decreased by 8.0 ± 5.7% (P<0.05) following hypoxia in WT mice 
(Table 3.1). The decline in peak flow velocity was approximately twice as great 
(16.2 ± 8.4%; P<0.05) in Enpp2+/- littermates after exposure to hypoxia (Table 3.1). 
Taken together, the greater increase in RVSP and decline in peak flow velocity 
across the pulmonary valve suggest Enpp2+/- mice are more sensitive to 
hypoxia-induced pulmonary vasoconstriction and hypertension. We also calculated 
the pulmonary velocity acceleration time from the echocardiography. However, 
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although used to monitor PAH in human, we could not see a significant difference 
between normoxic and hypoxic conditions. Therefore, the peak flow velocity 
between the pulmonary valves seems to be a more sensitive method to evaluate 
PAH in our case. The LV fractional shortening percentage was also obtained by 
echocardiography to verify whether the overall cardiac function was affected by 
hypoxia treatment. No significant change was found between baseline and 
post-treatments (data not shown).  
     To confirm that the changes in RVSP and peak flow velocity reflect 
differences in pulmonary vascular remodeling, muscularization of small pulmonary 
arterioles in response to hypoxia was examined.  Lung sections stained with 
α-smooth muscle actin, a marker for SMCs, were scored for non-, partially, and 
fully- muscularized small pulmonary arterioles. The pulmonary histology of 
Enpp2+/- mice was not notably different from WT controls at baseline. In particular, 
WT and Enpp2+/- littermates maintained in normal conditions did not differ in the 
percentage of non- or fully muscularized arterioles.  Following a 3-week exposure 
to hypoxia, an increase in the percentage of fully muscularized small arterioles 
occurred in WT mice, confirming the pulmonary vascular remodeling in our 
hypoxia model.   Relative to the WT controls, lungs from Enpp2+/- mice exposed 
to hypoxia had a higher percentage of fully-muscularized and a lower percentage of 
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non-muscularized distal small arterioles then did WT controls (Figure 3.3). The 
differences in pulmonary arteriolar muscularization percentage were statistically 
significant between hypoxic Enpp2+/- and WT controls (82% muscularized 
arterioles in Enpp2+/- mice versus 68.5% in WT mice; P<0.05). By all parameters, 
Enpp2+/- mice seemed to have exaggerated pulmonary vascular responses to 
hypoxia that was consistent with an augmentation in hypoxia-induced pulmonary 
hypertension. 
    The expression level of Enpp2 in the lung among different groups was 
examined by quantitative RT-PCR. As expected based on our previous findings of 
lower autotoxin/lysoPLD protein level in the lungs of Enpp2+/- mice 63,  Enpp2 
mRNA expression in lungs of Enpp2+/- mice was 20% of that in lungs from WT 
littermates.  No significant change in gene expression of Enpp2 occurred after 
hypoxia in either Enpp2+/- mice and WT littermates (Figure 3.4).  The expression 
level of LPA receptors in the lung was also measured. The lack of significant 
increase of Lpa1-5 in Enpp2+/- mice to WT littermates in both normoxic and 
hypoxic conditions suggests no compensatory up-regulation of LPA receptors in 
response to decreased Enpp2 level in the lung. On the contrary, levels of Lpa1-5 
were slightly but consistently lower in Enpp2+/- mice to WT in normoxic condition. 
Following exposure to hypoxia, while no obvious change in the expression patterns 
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of Lpa1-3 was seen, pulmonary Lpa4 and Lpa5 gene expression were consistently 
reduced in mice of both strains when compared to the normoxic groups, with Lpa4 
levels declining by 20 - 50% and Lpa5 levels by 30 - 40%. No obvious 
compensatory changes in other LPA receptors were observed with hypoxia 
exposure (Figure 3.5).  
  
Hypoxia-induced pulmonary remodeling in mice with increased 
autotaxin/lysoPLD and LPA levels 
Transgenic overexpression of Enpp2 in mice (Enpp2-Tg) increases plasma 
lysoPLD activity and LPA levels 63. To determine if increases in circulating LPA 
levels might protect from hypoxia-induced pulmonary hypertension, Enpp2-Tg and 
age-matched WT control mice were subjected to 3 weeks of hypoxia.  At baseline, 
Enpp2-Tg mice display normal RVSP (25.1 ± 6.9 mmHg; n =8) . RVSP increase 
following hypoxia in Enpp2-Tg was not significantly lower from WT control mice 
(33.8 ± 5.7 mmHg; n =9 for Enpp2-Tg versus 37.0 ± 5.1 mmHg; n =8 for WT)    
(Figure. 3.6). Although there was no significant difference in RVSP, Enpp2-Tg 
mice did display less decline in peak flow velocity across the pulmonary valve. 
Peak flow velocity across the pulmonary valve decreased by 15.6 ± 8.7% following 
hypoxia in WT mice. The decline in peak flow velocity was less (4.4 ± 6.8%; not 
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statistically significant) in Enpp2-Tg mice after exposure to hypoxia (Table 3.2). 
Together, our data suggest Enpp2-Tg mice may be protected from hypoxia-induced 
pulmonary hypertension, but the protective effect is rather moderate when 
comparing to the hypersensitivity of Enpp2+/- mice.      
Muscularization of small pulmonary arterioles in response to hypoxia was 
again used as an indicator for pulmonary vascular remodeling.  The percentage of 
distal arteriolar muscularization was very similar in WT and Enpp2-Tg mice post 
hypoxia (86.5% muscularized arterioles in Enpp2-Tg mice versus 83% in WT 
mice; not statistically significant) (Figure 3.7). However, interestingly, the 
percentage of muscularized arterioles was statistically higher in Enpp2-Tg mice to 
age-matched WT controls in normoxic condition (74.5% muscularized arterioles in 
Enpp2-Tg mice versus 42% in WT mice; P<0.05). Hence, the increase in arteriolar 
muscularization was very limited in Enpp2-Tg mice exposed to hypoxia. Enpp2-Tg 
mice seemed to be more resistant to hypoxia-induced pulmonary arteriolar 
remodeling. Taken together, Enpp2-Tg mice may display a moderate protective 
effect toward hypoxia-induced pulmonary hypertension.        
Expression of the human Enpp2 transgene is driven by the α1-anti-trypsin 
inhibitor promoter, which may result in expression in the lung. Therefore, primers 
specifically recognizing human Enpp2 mRNA were used to determine the 
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expression level of the transgene.  As expected, no human Enpp2 mRNA was 
detected in lung of WT mice. The exposure of Enpp2-Tg mice to hypoxia is 
associated with an approximately 50% reduction in human Enpp2 mRNA levels 
(Figure 3.8A), which may account for the lack of a significant phenotype in the 
transgenic mice with hypoxia.  There was no significant change of endogenous 
mouse Enpp2 mRNA level between WT and Enpp2-Tg in both normoxic and 
hypoxic conditions (Figure 3.8B). However, like human Enpp2 transgene, the 
expression of endogenous Enpp2 also decreased by 30% ~ 50% with hypoxia.    
mRNA levels of LPA receptors in the lung were measured to see whether their 
expression was affected by increased autotoxin/lysoPLD and LPA levels or hypoxia. 
Expression levels of Lpa1, 2, 4, and 5 were the same in Enpp2-Tg and age-matched 
WT mice, while Lpa3 was consistently lower in Enpp2-Tg mice. This indicates 
expression of Lpa3 may be down-regulated by excess LPA in the circulation. 
Following hypoxia, Lpa4 and Lpa5 declined in both WT and Enpp2-Tg mice while 
levels of other receptors remained relatively the same. Overall, no significant 
difference in receptor expression levels was found to suggest a role of specific 
receptors in hypoxia-induced pulmonary hypertension (Figure 3.9).    
    Since Enpp2+/- and Enpp2-Tg mice react differently to hypoxia-induced 
pulmonary hypertension, we also tested whether these mice spontaneously develop 
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pulmonary hypertension at different ages. As shown earlier, RVSP of young adult 
(2-3 months old) Enpp2+/- and Enpp2-Tg mice does not differ from their 
age-matched WT controls (Figure 3.2 and 3.6). In aged group (6 months and older), 
Enpp2+/- and Enpp2-Tg mice also displayed RVSP values in the normal range, and 
did not differ from their age-matched WT controls (data not shown). Therefore, we 
concluded Enpp2+/- and Enpp2-Tg mice did not spontaneously develop pulmonary 
hypertension without hypoxia stimulation.      
 
Discussion 
    In this chapter, we aimed to determine the regulatory effect of LPA in the 
pulmonary vasculature. Hypoxia was used as a challenge to pulmonary vasculature, 
and the reactivity of mice with genetically altered expression of autotoxin/lysoPLD 
and LPA levels to hypoxia was examined.  
    Mice were exposed to half of the normal oxygen concentration at normal 
atmospheric pressure for 3 weeks to induce pulmonary hypertension. The oxygen 
concentration and duration of our hypoxic condition was based on previous studies 
36
. The success of hypoxia-induced pulmonary hypertension was determined by 
increase in RVSP, decrease in peak flow velocity across the pulmonary valve, and 
increase of muscularized pulmonary arterioles in hypoxic WT animals, comparing 
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to littermates raised in room air (normoxia).     
Genetic manipulation that reduces the expression of autotoxin/lysoPLD and 
decreases circulating LPA levels in mice, promotes the development of pulmonary 
hypertension with hypoxia.  Thus, LPA may play a protective role by preventing 
hypoxia-induced pulmonary vasoconstriction. In contrast, mice overexpressing 
human autotaxin/lysoPLD may be mildly protected from hypoxia-induced 
changes, as suggested by preservation of peak flow velocity across the pulmonary 
valve. The moderate phenotype of the Enpp2-Tg mice may be limited by 
down-regulation of transgene expression that occurs during hypoxia and would be 
expected to reduce LPA levels.   Moreover, autotoxin/lysoPLD and LPA at 
physiologically normal levels may be sufficient for the protective effect, and 
further increases may provide no additional benefit. The fact that Enpp2-Tg mice 
show less reduction in peak flow velocity across the pulmonary valve, but no 
significant difference in RVSP to age-matched WT controls after hypoxia also 
suggests that the reduction in pulmonary flow is a more sensitive parameter that is 
subjected to change earlier in the progression of pulmonary hypertension.  
The percentages of muscularized arterioles in hypoxic condition were similar 
in Enpp2-Tg and control mice. However, interestingly, Enpp2-Tg mice showed a 
much higher percentage of muscularized vessels at baseline (normoxia) to 
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age-matched WT mice. We could not explain the possible mechanism behind it, and 
no abnormality in the overall pulmonary histology of Enpp2-Tg mice was found 
(data not shown). Nevertheless, the higher percentage of muscularized arterioles at 
baseline made the increase in muscularization after hypoxia very limited, if any, in 
Enpp2-Tg mice. In the sense, Enpp2-Tg mice seem to be more resistant to 
pulmonary vascular remodeling with hypoxia exposure.    
Enpp2+/- mice are bred by crossing Enpp2+/- and WT littermates, and therefore 
the control group is their WT littermates. The Enpp2-Tg colony is bred from the 
original Enpp2-Tg line, and their control group is age-matched WT mice from the 
same background. Enpp2+/- and Enpp2-Tg mice are both in the FVB background. 
Interestingly, the two WT groups show certain differences at baseline as well as 
responses to hypoxia. The RVSP values at normoxia were similar (25.7 ± 2.1 
mmHg of WT for Enpp2+/- and 24.9 ± 3.0 mmHg of WT for Enpp2-Tg). 
However, the WT for Enpp2-Tg had a higher RVSP value after hypoxia (37.0 ± 
5.1 mmHg versus 30.2 ± 2.3 mmHg of WT for Enpp2+/-). WT for Enpp2-Tg 
also showed ~2 fold more reduction in peak flow velocity across the pulmonary 
valve after hypoxia (-15.6 ± 8.7 % versus -8.0 ± 5.7 % of WT for Enpp2+/-). 
As to pulmonary vascular remodeling, the muscularization percentages of 2 WT 
groups were similar at baseline. However, in the hypoxic group, the percentage of 
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non-muscularized arterioles was 32% in WT for Enpp2+/- and only 17% in WT for 
Enpp2-Tg. Overall, by all parameter looked, the WT for Enpp2-Tg showed 
exacerbated response toward hypoxia. The differential responses can be attributed 
to strain variations. Although both Enpp2+/- and Enpp2-Tg mice are on the FVB 
background, the Enpp2-Tg are the on the FVB/NJ background, and the Enpp2+/- 
mice are the European FVB sub-strain, which was transferred from the US to 
Amsterdam in 1978. The two sub-strains are kept separately for decades, and 
therefore there may be genetic drifts between the FVB/NJ mice and the FVB line 
used in Europe that could account for the differential responses. In addition, the WT 
littermates for Enpp2+/- mice are congenic which were back-crossed at least 10 
times to FVB background, while the WT used for Enpp2-Tg are isogenic FVB mice. 
The SV-129 genes left in the congenic mice may account for the differential 
responses. Nevertheless, the baseline values of RVSP and peak flow velocity across 
the pulmonary valve were similar between Enpp2+/-, Enpp2-Tg and their respective 
WT controls.  
In this chapter, we demonstrate a novel role for LPA in the regulation of 
pulmonary vasculature. By studying mouse models with elevated and reduced 
LPA levels, our data suggest that circulating LPA levels are necessary for the 
maintenance of normal pulmonary vascular tone. The next question is how LPA 
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signaling regulates the pulmonary vasculature and which receptor(s) mediate the 
effect. The expression levels of Lpa 1-5 in the lung are measured. The expression of 
Lpa4 and 5 were down-regulated with hypoxia in all strains (Enpp2+/-, Enpp2-Tg 
and their respective WT controls). No obvious compensatory expression in any 
specific genotypes upon treatment was found. Therefore, the specific receptor(s) 
mediating the protective effect of LPA to pulmonary hypertension remains to be 
determined.    
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Figure 3.1. Progression of hypoxia-induced pulmonary hypertension .
Lungs sections from normoxic and hypoxic mice were stained with α-smooth muscle actin
(red) to show increased muscularization and wall thickness of pulmonary arterioles as signs
of pulmonary remodeling in the hypoxic group.
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Figure 3.2. The response of mice with reduced ATX levels (Enpp2+/-) to hypoxia.
Right ventricular systolic pressure (RVSP) of WT (n=6) and Enpp2+/- (n=5) mice in normoxia,
and WT (n=6) and Enpp2+/- (n=7) mice 3 weeks with hypoxia. Individual values (dots) and
medium with 25 and 75 confidence intervals (box plots) are presented. Data were analyzed by 2-
way ANOVA. *P<0.05.
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Table 3.1. Peak flow velocity across the pulmonary valve before and after 3 weeks of exposure to 
normoxia or hypoxia.
Genotype Condition N Before After
WT Normoxia 4 878.79 ± 44.38 993.05 ± 69.58
WT Hypoxia 6 898.85 ± 76.3 824.52 ± 55.3
Enpp2+/- Normoxia 5 927.71 ± 65.61 922.96 ± 41.22
Enpp2+/- Hypoxia 7 960.68 ± 92.91 802.29 ± 94.79
Results are presented as mean ± SD in mm/sec. 
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Figure 3.3. Percentages of muscularization of distal pulmonary arterioles in normoxic or hypoxic
WT and Enpp2+/- mice.
Lung sections were immunostained with α-smooth muscle actin and scored as described in
Materials and Methods. non= non muscularized vessels, partial= partially muscularized vessels, and
full= fully muscularized vessels. Data are presented as averages of 4 mice/group and analyzed by 2-
way ANOVA. *P<0.05.
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Figure 3.4. ATX expression level in lung of mice with lowered ATX levels (Enpp2+/- ) with
hypoxia.
Quantitative RT-PCR analysis of autotaxin/lysoPLD (ATX) expression level in lung of
littermates of WT (slashed bars) and Enpp2+/- (open bars) mice in normoxic and hypoxic
conditions. All Results were graphed from four experiments and presented as mean ± S.D.
The expression level from WT mice in normoxic condition is set as 1. *P<0.05 .
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Figure 3.5. Expression level of LPA receptors in the lung of Enpp2+/- mice.
Quantitative RT-PCR analysis of LPA1-5 expression level in lung of littermates of WT
(slashed bars) and Enpp2+/- (open bars) mice in normoxic and hypoxic conditions. All results
were graphed from four experiments and presented as mean ± S.D. The expression level of
WT mice in normoxic condition is set as 1. *P<0.05 .
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Figure 3.6. The response of mice with elevated ATX levels (Enpp2-Tg) to hypoxia.
Right ventricular systolic pressure (RVSP) of WT (n=8) and Enpp2-Tg (n=8) mice in normoxia,
and of WT (n=8) and Enpp2-Tg (n=9) mice 3 weeks with hypoxia. N=8 for both WT and
Enpp2-Tg mice in normoxia. N=8for WT and 9 for Enpp2-Tg mice in hypoxia. Individual
values (dots) and medium with 25 and 75 confidence intervals (box plots) are presented. Data
were analyzed by 2-way ANOVA. *P<0.05.
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Table 3.2. Peak flow velocity across the pulmonary valve of mice before and after 3 weeks of
exposure to normoxia and hypoxia.
Genotype Condition N Before After
WT Normoxia 5 1004.28  ± 43.89 946.70  ± 60.08
WT Hypoxia 5 963.81    ± 64.84 808.30  ± 38.42
Enpp2-Tg Normoxia 5 1040.56  ± 41.54 1026.97 ± 51.09
Enpp2-Tg Hypoxia 5 1018.06  ± 111.29 967.09  ± 57.34
Results are presented as mean ± SD in mm/sec.
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Figure 3.7. Muscularization of distal pulmonary arterioles in normoxic or hypoxic WT and
Enpp2-Tg mice.
Lung sections were immunostained with α-smooth muscle actin and scored as described in
Materials and Methods. Data are presented as averages of 4 mice/group and analyzed by 2-way
ANOVA. *P<0.05.
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Figure 3.8. ATX expression level in lung of mice with elevated ATX levels (ATX-Tg) with
hypoxia exposure.
A. Quantitative RT-PCR analysis of human ATX transgene expression level in lung of ATX-Tg
(closed bars) mice in normoxic and hypoxic conditions.
B. Quantitative RT-PCR analysis of endogenous mouse ATX expression level in lung of age-
matched WT (slashed bars) and Enpp2-Tg (closed bars) mice in normoxic and hypoxic conditions.
All Results were graphed from four experiments and presented as mean ± S.D. The expression
level from WT mice in normoxic condition is set as 1.
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Figure 3.9. Expression levels of LPA receptors in lung of Enpp2-Tg mice.
Quantitative RT-PCR analysis of LPA1-5 expression level in lung of littermates of WT (slashed
bars) and Enpp2-Tg (closed bars) mice in normoxic and hypoxic conditions. All results were
graphed from four experiments and presented as mean ± S.D. The expression level of WT mice in
normoxic condition is set as 1. *P<0.05.
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Chapter 4 
LPA receptors 1 and 2 in pulmonary vascular regulation 
 
Introduction 
A family of G protein-coupled receptors (GPCRs) is at least partially 
responsible for the cellular responses of LPA. At present, there are five bona fide 
LPA receptors, LPA1-5 62,73, with evidence for at least three more (LPA 6 – 8)74,75. 
LPA receptors 1 – 5 are expressed ubiquitously in most mammalian tissues. In vitro 
studies in cell lines reveal that LPA receptors share certain function redundancy as 
well as specificity 62,79,80. Until recently, understanding the physiologic role of these 
receptors has been hampered by lack of subtype specific, selective receptor agonists 
and antagonists.  However, genetic deletion of LPA receptors has provided 
valuable information on their pathophysiological roles 127. For example, deficiency 
of Lpa1 in mice generates craniofacial abnormalities, reduced size, a small 
incidence of perinatal frontal hematoma, and 50% neonatal lethality 81, whereas 
deletion of Lpa3 results in implantation defects82,83.  Lpa2-deficient and 
Lpa4-deficent mice display no obvious phenotypes 84,85, although cells from 
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Lpa4-deficient mice display enhanced migration in response to LPA85. Mice 
deficient of both Lpa1 and Lpa2 present similar abnormities as knocking out Lpa1 
alone except an increased incidence of frontal hematoma 84. 
LPA is an effective modulator in the cardiovascular system.  Its production is 
facilitated by activated platelets, and it has multiple effects on vascular SMCs and 
endothelial cells.  For example, LPA is well-known for its phenotypic modulating 
effect on cultured vascular SMCs by promoting their de-differentiation, 
proliferation, and migration 88-90. LPA promotes endothelial cell migration that 
involves organization of the actin cytoskeleton and the extracellular matrix 101,102. 
LPA has been variably reported to increase or decrease endothelial barrier function 
103
. By using quantitative RT-PCR analysis, others and our lab had established that 
LPA1 and LPA2 expressed relatively high levels in vascular SMCs and endothelial 
cells 128,129. Given that LPA is poised to be a mediator of vascular disease, we are 
interested in characterizing the vascular phenotype of mice lacking LPA receptors 1 
and 2 (LPA1-/-2-/- mice) 84. 
To date, not much has been reported regarding the cardiovascular and 
pulmonary-related phenotypes of LPA1-/-2-/- mice. Our group recently reported the 
roles of LPA1 and LPA2 in regulation of phenotypic modulation of vascular SMCs 
after injury 100.  LPA1-/-2-/- mice were partially protected from developing carotid 
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ligation and femoral artery denudation-induced neointimal hyperplasia, whereas 
LPA1-/- mice developed larger neointimal lesions after injury. The injury-induced 
response of LPA2-/- mice was similar to that of WT mice. Growth in serum, 
LPA-induced extracellular signal-regulated ERK activation, and migration to LPA 
and serum were all attenuated in SMCs isolated from LPA1-/-2-/- mice. In contrast, 
LPA1-/- SMCs exhibited enhanced migration resulting from an up-regulation of 
LPA3. However, despite their involvement in intimal hyperplasia, neither LPA1 nor 
LPA2 was required for dedifferentiation of SMCs following vascular injury or 
dedifferentiation of isolated SMCs in response to LPA or serum in vitro. Similarly, 
neither LPA1 nor LPA2 was required for the transient increase in systemic blood 
pressure following intravenous administration of LPA to mice. These results 
identify a role for LPA1 and LPA2 in regulating SMC migratory responses in the 
context of vascular injury.  
In bleomycin-induced lung injury models, endothelial permeability is 
mediated by the LPA1 receptor 109. Pulmonary fibrosis was markedly inhibited in 
LPA1-/- mice, and these mice were protected from mortality after bleomycin 
treatment. The lack of LPA1 led to reduced fibroblast recruitment. LPA levels in 
bronchoalveolar lavage fluid were increased, and inhibition of LPA1 significantly 
reduced fibroblast responses to the chemotactic activity in idiopathic pulmonary 
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fibrosis patients. 
Given our preliminary data of the protective effect of LPA on hypoxia-induced 
pulmonary hypertension, and the high expression levels of LPA1 and LPA2 in 
endothelial and SMCs, we sought to determine whether LPA1 and LPA2 participate 
in the regulatory effect of LPA in the pulmonary vasculature. 
 
Materials and Methods 
Mice 
All procedures conformed to the recommendations of Guide for the Care and Use 
of Laboratory Animals (Department of Health, Education, and Welfare publication 
number NIH 78-23, 1996) and were approved by the Institutional Animal Care and 
Use Committee. Generation and characterization of LPA1-/-2-/- mice were as 
previously described 81,84. The LPA1-/-2-/- mice were backcrossed for >10 
generations to the Balb/c background. Mice were housed in cages with HEPA 
filtered air in rooms on 12-hour light cycles and fed Purina 5058 rodent chow ad 
libitum.  
Hypoxia model 
This method was stated in chapter 3.   
Echocardiography 
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This method was stated in chapter 3. 
RV pressure measurement 
This method was stated in chapter 3. 
Real-time PCR 
This method was stated in chapter 3. 
Histology 
Mice were weighed, and hearts, lungs, livers, and kidneys were dissected, rinsed in 
PBS, and weighed. Hearts were cut in a cross section at the widest point. The top 
half of the heart was fixed with 4% paraformaldehyde and embedded in paraffin. 5 
µm sections of hearts and lungs were prepared with microtome. The sections were 
stained with hematoxylin and eosin (H&E) for examination of gross appearance, 
whereas Masson’s Trichrome, periodic acid-Schiff, counterstained with 
hematoxylin (PAS-H), and van Gieson elastin staining was employed to facilitate 
quantification of fibrosis, cardiomyocyte size, and elastin content respectively. 
Thickness of LV and RV free walls and total cross-section diameter of the heart was 
measured at the level of LV papillary muscles in H&E stained sections. 
Measurements were made at 3 individual sites and averaged 130,131. Cardiomyocyte 
hypertrophy was assessed by measuring cross-sectional area of 50 cardiomyocytes 
with nearly circular capillary profiles and centered nuclei in randomly selected 
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fields in the LV or RV free walls per PAS-H-stained section.132 To perverse the 
pulmonary architecture, lungs were tracheal perfused with 4% paraformaldehyde at 
25cm pressure for 10 minutes in some cases. 133 The morphology, muscularization 
percentage of small arterioles, and arteriolar wall thickness were quantified with 
lung sections immunostained with the biotinylated anti- α-smooth muscle actin 
antibody (Sigma). The dilution of the antibody was 1 to 100 in PBS. Small 
arterioles with diameters ranging in 15-100 µm were scored. Arterioles with no 
positive α-smooth muscle actin staining were characterized as non-muscularized, 
wrapped with 0-75% positive staining as partially-muscularized, and >75% 
positive staining as fully-muscularized vessels. 50 arterioles in each section were 
counted for muscularization percentage. For quantification of pulmonary vascular 
wall thickness, pictures of small arterioles with diameters ranging in 15-100 µm are 
taken and analyze with Metamorph image software. The outer and inner diameter of 
each arterioles are measured, and the arteriolar wall thickness was calculated by the 
formula: wall thickness was calculated as (outer vessel circumference/2π) – 
(circumference of lumen/2π) 134. 25 arterioles in each section were quantified for 
pulmonary vascular wall thickness. Van Gieson elastin staining was used to stain 
elastin and collagen in the lung sections. Perivascular elastin deposition was 
quantified by the density of positive elastin staining on the vascular wall and 
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normalized by vascular diameters using Metamorph image software.  
Oxygen saturation 
Mice were lightly anesthetized with isoflurane. The real-time oxygen saturation of 
arterial hemoglobin, heart rate, pulse distension, breath distension, and respiratory 
rate were obtained and analyzed with mouseOx (Starr) by placing a sensor on the 
right thigh of the mouse.  
Hematological analysis 
Retro-orbital bleeding was performed with mice anesthetized with isoflurane. 
Whole blood was collected into EDTA-coated tubes. Hemoglobin concentration 
and hematocrit were analyzed with ABC vet hematology analyzer (ABX) set to 
measure mouse blood cell parameters. 
Pulmonary vascular permeability 
Mice were kept anesthetized with pentobarbital. The neck skin was cut open, and 
1% Evans blue in PBS was injected into the right jugular vein (100µl / mice). 15 
minutes later, heparin with PBS was perfused from RV to LV at a constant rate of 
111.8 ml/hr (25 mmHg pressure). The perfused lung was dissected, weighed and 
immersed in 1ml formamide to extract Evans blue. The extraction was performed in 
a shaking water bath at 56ﾟC for 24 hours. The extracted Evans blue was quantified 
by reading absorbance at 600 nm and normalized to lung weight.      
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Statistics 
This method was stated in chapter 3. 
 
Results 
LPA1-/-2-/- mice develop pulmonary hypertension with age  
In chapter 3, we found that mice with reduced circulating autotoxin/lysoPLD 
and LPA levels (Enpp2+/- mice) are prone to develop pulmonary hypertension with 
hypoxia exposure. LPA receptors 1 and 2 were reported to be abundantly 
expressed in cultured endothelial and vascular SMCs, and we observed relatively 
high expression levels in murine blood vessels.  We therefore were interested in 
understanding whether these 2 receptors are involved in regulating the pulmonary 
vasculature.  
   Young LPA1-/-2-/- mice (8 – 14 weeks old) did not display a significant increase 
in RVSP when comparing to age-matched WT controls (37.9 ± 8.8 mmHg in 
LPA1-/-2-/- mice versus 28.6 ± 8.0 mmHg in WT mice; not statistically significant) 
(Figure 4.1A). When measuring RVSP in aged mice (over 45 weeks old), we 
observed a significant increase in pressures of LPA1-/-2-/- mice when comparing to 
WT mice (58.5 ± 4.5 in LPA1-/-2-/- mice versus 28.6 ± 8.0 mmHg in WT mice; 
P<0.05) that did not occur in mice singly deficient of LPA1 (LPA1-/-) or LPA2 
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(LPA2-/-) (Figure 4.1B). 
In agreement with the age-dependent elevation in RVSP observed in 
LPA1-/-2-/- mice, peak flow velocity across the pulmonary valve was 11% lower in 
LPA1-/-2-/- (613 ± 125 mm/sec; n = 18) than in WT (690 ± 94 mm/sec; n= 22; not 
statistically significant) mice at 2 – 3 months of age. The decline became more 
evident with age, as the peak flow velocity was 18% lower in the LPA1-/-2-/- mice 
(573 ± 70 mm/sec; n = 14) than WT controls (698 ± 92 mm/sec; n=11; P<0.05) by 
6 – 9 months of age, (Table 4.1). In comparison to the decline in peak flow velocity 
in LPA1-/-2-/- mice over time, the WT mice in two age groups displayed almost the 
same values. Taken together, our findings indicate LPA1-/-2-/- mice develop 
spontaneous pulmonary hypertension with age.   
To determine whether the elevation of RVSP was reflected in histology, we 
examined the heart cross-sections of aged WT and LPA1-/-2-/- mice for RV 
hypertrophy. The RV free wall was notably thicker, and RV chamber was dilated in 
the representative pictures of LPA1-/-2-/- heart to age-matched WT controls (Figure 
4.2A). Quantification showed significantly higher RV free wall thickness to 
cross-section diameter ratio of aged LPA1-/-2-/- mice (0.17 ± 0.05) comparing to 
age-matched WT mice (0.10 ± 0.02; P<0.05). There was no difference among 
WT and single knockout mice (LPA1-/- and LPA2-/-mice) (Figure 4.2B). 
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To confirm the thickening of RV free wall was due to RV hypertrophy, we 
measured the cross-section area of individual cardiomyocytes and numbers of 
nuclei per microscopic field in RV and LV of aged WT and LPA1-/-2-/- heart sections. 
Average cardiomyocyte size was significantly greater in RV of LPA1-/-2-/- mice 
comparing to WT controls (179 ± 57% in LPA1-/-2-/- RV versus 100 ± 5% in 
WT RV; P<0.05), while the nuclei numbers per field stayed the same. 
Cardiomyocyte size and nuclei numbers were very similar in LV of both genotypes, 
indicating the size increase of cardiomyocyte happened specifically in RV (Figure 
4.3).  Hence, we confirmed that in agreement with the increase in RVSP, the 
LPA1-/-2-/- mice developed RV hypertrophy with age. No histological evidence of 
cardiac fibrosis or inflammation was found in the LPA1-/-2-/- heart sections. Taken 
together, these physiological and histological changes further confirmed the 
development of pulmonary hypertension in LPA1-/-2-/- mice with age. 
To look for the possible mechanism of the spontaneous development of 
pulmonary hypertension, we examined parameters that cause secondary pulmonary 
hypertension. We excluded hypoxia as a cause for pulmonary hypertension in the 
LPA1-/-2-/- mice. Arterial oxygen saturation in WT mice were 96 ± 1% and 97 ± 
1% at 1 - 2 months and 6 months of age, respectively.  Corresponding values in 
the LPA1-/-2-/- mice were 95 ± 2%,  97 ± 0.3%  and 96 ± 2% at 1 - 2 months, 3 – 
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4 months and >6 months of age, respectively (Figure 4.4A).  Additionally,  
hemoglobin (17.6 ± 1.3 g/dl) and hematocrit values (53.3 ± 4.4 %) in LPA1-/-2-/- 
mice did not differ from age-matched WT (17.4 ±1.6 g/dl and 55.3 ± 7.9 %), 
indicating that the LPA1-/-2-/- mice did not develop secondary polycythemia, 
which would be expected to occur in the setting of prolonged hypoxia (Figure 
4.4B and C). We also examined whether pulmonary vascular permeability was 
changed in LPA1-/-2-/- mice. Evans Blue dye was injected into the jugular vein of 
WT and LPA1-/-2-/- mice. After perfusion the pulmonary circulation at physiological 
relevant pressure, Evans blue leaked into the lung tissue was extracted and 
quantified. The average amount of extracted Evans Blue was the same in WT and 
LPA1-/-2-/- mice, suggesting normal permeability of the pulmonary vasculature in 
LPA1-/-2-/- mice (0.9 ± 0.3 in LPA1-/-2-/- mice versus 1.0 ± 0.4 in WT mice) 
(Figure 4.5A). In accordance to normal pulmonary permeability, no evidence of 
edema was seen in the lung tissue of LPA1-/-2-/- mice. Examination of pulmonary 
valves did not reveal any notable abnormalities of LPA1-/-2-/- mice, excluding 
pulmonary stenosis as a cause for the elevated RVSP (Figure 4.5B). Plastic casting 
and microCT analysis of the pulmonary vasculature also did not reveal obvious 
obstruction in the main pulmonary vasculature (data not shown).        
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Abnormal pulmonary development in LPA1-/-2-/- mice  
    Normal pulmonary vascular formation is critical for lung alveolarization, 
which requires coordinated growth and differentiation of pneumocytes, endothelial 
cells and vascular SMCs.  In mice, the final stage of lung development occurs 
postnatally, when primary air saccules divide into smaller air spaces through the 
process of secondary septation 1,2. When we analyzed lung sections for the 
pulmonary vascular remodeling, we noted enlarged alveoli in the lung section of 
LPA1-/-2-/- mice, and sought to characterize their pulmonary development more 
carefully. Histological examination of the lung sections from 12-week old 
LPA1-/-2-/- mice revealed an increase in the size of alveolar space. The process of 
alveolar septation in mice is largely complete by 3 weeks of age, at which time 
alveolar enlargement was already present in LPA1-/-2-/- mice (Figure 4.6). At 3 
weeks of age, there was an increase in the muscularization of pulmonary arterioles 
in LPA1-/-2-/- mice comparing to age-matched WT controls (preliminary data; n=2), 
and the increased muscularization became more evident at 12 weeks (63% 
muscularized arterioles in LPA1-/-2-/- mice versus 18% in WT mice; P<0.05) 
(Figure 4.8A).  Histological examination of lung sections at postnatal day 3 (P3) 
and 7 (P7) did not reveal any obvious changes in the lung architecture in 
LPA1-/-2-/- mice, and therefore the impairment of lung development was likely to 
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occur between P7 and P21. (Figure 4.6).   
Because the level of elastin, one of the major ECM components in the lung, 
may affect normal lung development as well as vascular pressure, we measured 
elastin gene expression (Eln) in lungs of LPA1-/-2-/- mice, and found that Eln 
expression was 1.9 ±0.37 fold in LPA1-/-2-/- than in WT controls.  At 3 weeks of 
age, LPA1-/-2-/- mice had a similar 2-fold elevation of Eln as compared to WT 
controls (Figure 4.7A).  To determine whether the up-regulation of Eln is 
reflected in elastin deposition, elastin staining of lung sections was performed. 
Representative pictures show increased black elastin staining surrounding vessels 
of various sizes in the lungs of LPA1-/-2-/- mice (Figure 4.7C). Quantification of 
elastin content around the vessels confirmed greater perivascular elastin 
deposition in LPA1-/-2-/- mice at both 3 and 12 weeks of age (1.7 ± 0.2 fold 
increase for 3 weeks old and 2.5 ± 0.6 fold increase for 12 weeks old LPA1-/-2-/- 
mice) (Figure 4.7B). 
 
Enhanced hypoxia-induced pulmonary remodeling in mice with deficiency of 
LPA1 and LPA2 receptors 
Having acknowledged that aged LPA1-/-2-/- mice had increased RVSP, we 
hypothesized that LPA1-/-2-/- mice may be susceptible to hypoxia-induced 
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pulmonary hypertension and remodeling as were mice with reduced LPA level 
(Enpp2+/-). Young LPA1-/-2-/- mice (8 – 14 weeks old) did not display a significant 
increase in RVSP when comparing to age-matched WT controls (Figure 4.1A) and 
were subjected to hypoxia for 3 weeks. Similar to Enpp2+/- mice, an 
approximately 2-fold reduction in peak flow velocity across the pulmonary valve 
occurred in LPA1-/-2-/- mice after hypoxia (25.3 ± 16.9% of LPA1-/-2-/- mice 
versus 13.8 ± 16.3% of WT mice; not statistically significant) (Table 4.2).  
Muscularization of small pulmonary arterioles was used to confirm that the 
changes in peak flow velocity reflected in pulmonary vascular remodeling in 
response to hypoxia. In agreement with the finding that LPA1-/-2-/- mice develop 
greater decline in peak flow velocity across the pulmonary valve, analysis of the 
lungs revealed more muscularized and less non-muscularized pulmonary arterioles 
in LPA1-/- 2-/- mice as compared to age-matched WT controls in response to 
3-week exposure to hypoxia (86.5% muscularized arterioles in LPA1-/-2-/- mice 
versus 53% in WT mice; P<0.05) (Figure 4.8A). Proliferation of vascular SMCs 
not only increases the percentage of muscularized small arterioles, but also 
increases the thickness of vascular wall. Consistent with the increase in the number 
of muscularized arterioles, the average thickness of pulmonary arteriolar wall was 
significantly higher in LPA1-/-2-/- mice than WT controls with hypoxia treatment 
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(Figure 4.8B). Interestingly, the fact that LPA1-/-2-/- mice had less 
non-muscularized and more muscularized vessels, as well as thicker pulmonary 
arteriolar wall to WT controls in normoxia revealed more pulmonary vascular 
remodeling of LPA1-/-2-/- mice at baseline (Figure 4.8). This implies that there may 
be certain degree of defect in the pulmonary vasculature of LPA1-/-2-/- mice prior to 
any stimulation. Similar to elevated RVSP with age, the absence of LPA1 and 
LPA2 may be associated with spontaneous pulmonary arterial remodeling.    
Sustained elevation in RVSP stimulates RV hypertrophy with increases in 
cardiomyocyte mass and RV free wall thickness.  Figure 4.9A shows 
representative pictures of heart cross-sections of WT and LPA1-/-2-/- mice in 
normoxic and hypoxic conditions. A thicker RV free wall was observed in the 
hypoxic LPA1-/-2-/- heart. Quantification of heart cross-sections revealed increase 
in the RV free wall thickness to total cross-section diameter in both WT and 
LPA1-/-2-/- mice after hypoxia, indicating our model of hypoxia-induced pulmonary 
hypertension was sufficient to trigger RV hypertrophy (Figure 4.9B). Higher RV 
free wall thickness to cross-section diameter ratio of LPA1-/-2-/- mice to WT 
controls in normoxia indicate the spontaneous development of RV hypertrophy of 
LPA1-/-2-/- mice. Together, LPA1-/-2-/- mice showed greater decline in peak flow 
velocity, more muscularization and increased pulmonary arteriolar wall thickness, 
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and RV hypertrophy with hypoxia treatment. These findings suggest that mice with 
impaired LPA signaling with lack of LPA1 and 2 are hyper-responsive to 
hypoxia-induced pulmonary hypertension.  
We measured gene expression levels of LPA receptors 1 - 5 in lungs of mice 
to determine if their expression was altered in the absence of LPA1 and LPA2. As 
expected, no Lpa1 or Lpa2 gene expression in lungs from LPA1-/-2-/- mice could 
be detected. The expression levels of Lpa4 and Lpa5 were higher in LPA1-/-2-/- to 
WT lung at baseline, but not as obvious with hypoxia exposure. Interestingly, the 
up-regulation of Lpa3 mRNA level that was observed in WT controls following 
exposure to hypoxia did not occur in the lungs of LPA1-/-2-/- mice (Figure 4.10).  
 
Discussion 
In this chapter, we found LPA1-/-2-/- mice developed spontaneous pulmonary 
hypertension with age. While the RVSP of young adult LPA1-/-2-/- and WT mice 
showed no obvious difference, the RVSP of aged LPA1-/-2-/- mice was 
significantly elevated than age-matched WT controls mice (58.5 ± 4.5 in 
LPA1-/-2-/- mice versus 28.6 ± 8.0 mmHg in WT mice, p<0.05). LPA1-/- mice may 
also display a slightly higher RVSP than WT controls, but the difference was not 
significant. Lacking LPA1 may have partial effect on the age-dependent 
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development of pulmonary hypertension. Nevertheless, neither LPA1-/- and 
LPA2-/- mice display the significant elevation of RVSP observed in the LPA1-/-2-/- 
mice, suggesting redundant signaling pathways between these two receptors. The 
spontaneous development of pulmonary hypertension in aged LPA1-/-2-/- mice was 
further confirmed by decline in peak flow velocity across the pulmonary valve as 
well as RV hypertrophy. 
No obvious compensatory up-regulation of other LPA receptors was found in 
the lungs of LPA1-/-2-/- mice. The higher expression levels of Lpa4 and 5 in 
normoxic LPA1-/-2-/- mice were not seen in the hypoxic group. Interestingly, the 
up-regulation of Lpa3 in hypoxic WT mice was not seen in hypoxic LPA1-/-2-/- 
mice, indicating LPA3 might also participate in the responses to hypoxia, and 
lacking certain LPA receptors, such as LPA1 and LPA2 in this case, may affect the 
signaling of other receptors. 
After establishing that LPA1-/-2-/- mice were susceptible to hypoxia-induced 
pulmonary remodeling and develop spontaneous pulmonary hypertension with age, 
we sought to determine the possible cause(s). As discussed earlier, chronic 
hypoxia contribute to pulmonary hypertension, and therefore we first checked the 
arterial oxygen saturation percentage at various ages. The oxygen saturation of 
LPA1-/-2-/- mice was within the normal range from 6 to 36 weeks old. In addition, 
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markers for prolonged hypoxia, such as increase in hemoglobin and hematocrit 
values were not seen in LPA1-/-2-/- mice. We therefore excluded hypoxia as the 
cause.  
Valvular diseases and obstruction in the pulmonary vasculature could also 
lead to pulmonary hypertension. By examining tissue sections, we did not find 
signs for pulmonary valve stenosis or other histological evidence to suggest 
valvular disease as a likely cause for pulmonary hypertension. The lack of 
pulmonary valve stenosis was further supported by the fact that LPA1-/-2-/- mice 
showed decreased peak flow velocity across the pulmonary valve rather than 
increase, which would be expected in the case of pulmonary valve stenosis. No 
architectural defect in the main pulmonary vasculature was noted by plastic 
casting and microCT analysis (data not shown). Examination of the lung tissue 
sections also failed to find evidences for thromboembolism or cor pulmonale.  
Endothelial cell plays a key role in the regulation of pulmonary vascular tone 
by balancing the vasoconstrictive and vasodilatory factors, and therefore 
endothelial dysfunction could contribute to pulmonary hypertension. To determine 
the integrity of the endothelial layer, we checked the pulmonary endothelial 
permeability by measuring the leakage of Evans blue dye into the lung tissue. No 
significant increase in pulmonary endothelial permeability was found in LPA1-/-2-/- 
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mice. We also challenged age-matched WT and LPA1-/-2-/- mice with hypoxia and 
performed the permeability assay. No difference was found in hypoxia-challenged 
mice either (data not shown). However, interestingly, we did not see an increase in 
pulmonary permeability with hypoxia exposure as other groups reported. This 
could be attributed to different hypoxia conditions, such as the hypobaric hypoxia 
model used by other groups 135,136. Another explanation is that we could not 
perform the pulmonary permeability assay in the hypoxic environment. Therefore, 
the endothelial layer could revert to normal shortly after the mice were taken out 
from the hypoxic chamber, so that we were not able to detect the change in time. 
Transmission electron microscopy was performed for a detailed look of the 
pulmonary endothelial cells, and the lining of endothelium appeared to be intact in 
the lung of LPA1-/-2-/- mice (data not shown).  
Overall, no striking histological changes, such as fibrosis, inflammation, and 
edema, were found in the lung and heart of LPA1-/-2-/- mice. Therefore the cause 
for the pulmonary hypertension may be more subtle and molecular-based effect 
rather than architectural changes of the pulmonary vasculature.      
While looking for histological evidences, we noticed enlarged alveoli in the 
lung of LPA1-/-2-/- mice. We therefore fixed the alveolar structure by 
paraformaldehyde perfusion through trachea and confirmed the enlargement of 
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alveoli in LPA1-/-2-/- mice at both 3 and 12 weeks of age. Since murine pulmonary 
development is not complete until 3 weeks after birth, the lack of LPA1 and 2 may 
likely result in impaired alveolarization, rather than disruption of the existing 
alveoli such as that occurs with emphysema. No evident difference at postnatal 
day 3 and 7 were seen in the lung architecture of LPA1-/-2-/- mice, suggesting the 
impairment of pulmonary development likely occurred between postnatal day 7 
and 21, the time of alveolar septation in mice.  
The disrupted pulmonary development in LPA1-/-2-/- mice may be associated 
with the development of pulmonary hypertension. The percentages of 
muscularized arterioles were higher in both 3 and 12 weeks old LPA1-/-2-/- mice, 
comparing to age-matched WT controls, suggesting the vascular remodeling was 
evident as early as 3 weeks of age (50% of muscularized vessels in LPA1-/-2-/- 
mice versus 30% in WT mice). The difference in 12 weeks old mice was even 
greater (63% in LPA1-/-2-/- mice versus 18% in WT mice), indicating the 
progression of vascular remodeling with age. The pulmonary histology of LPA1-/- 
and LPA2-/- mice appears to be normal without alveolar enlargement. This again 
suggested the redundancy of these receptors in the regulation of pulmonary 
vasculature (data not shown). To determine whether lacking LPA 1 and 2 in mice 
affects other vascular beds, we performed fundoscopy test to examine the retinal 
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microvasculature of LPA1-/-2-/- and WT mice. No notable difference was found in 
the retinal microvasculature, suggesting the changes in the pulmonary vasculature 
were unique (data not shown). 
Adequate composition and cross-linking of extracellular matrix (ECM) are 
keys to the development as well as maintenance of the vascular tone in the 
pulmonary vasculature 137. Since elastin is the major ECM component of 
mammalian lung 138, we sought to determine whether the elastin deposition was 
affected in LPA1-/-2-/- mice. LPA1-/-2-/- mice expressed higher level of eln at both 3 
and 12 weeks of age. In accordance to gene expression, the perivascular elastin 
content was also higher in these mice. Perivascular elastin deposition is tightly 
associated with hypertension. Increased elastin deposition was reported to occur in 
the arterial wall together with or very shortly after blood pressure elevation, and 
the deposition was proportional to pressure elevation 139. On the other hand, 
studies have shown that increased elastin deposition could be the cause rather than 
the consequence for hypertension. Baccarini-Contri and colleagues found that 
augmented elastin deposition occurred in young spontaneously hypertensive rats 
(SHR) before full establishment of hypertension, and even in fetal and neonatal 
rats 140. Briones and colleagues further incubated isolated SHR arteries with 
elastase to degrade elastin, and found the elastase incubation reversed the 
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structural and mechanical alterations of the arteries that were remodeled due to 
hypertension 141. We did not know whether the increase of elastin was the cause of 
pulmonary hypertension, or simply a reflection of the high arterial pressure in 
LPA1-/-2-/- mice. If impaired LPA signaling results in increased elastin expression, 
which leads to pulmonary hypertension, we would expect to see down-regulation 
of eln expression by activation of LPA signaling. However, our preliminary cell 
culture data suggest that LPA stimulates eln expression in primary cultured 
pulmonary arterial SMCs. Therefore the up-regulation of eln in LPA1-/-2-/- mice 
may reflect the increase in pulmonary arterial and/or abnormal vascular 
development in the LPA1-/-2-/- mice.  
As in chapter 3, we also used hypoxia as a model to test the pulmonary 
vascular reactivity. We found signaling through LPA1 and LPA2 may mediate the 
effect of LPA in the regulation of pulmonary vasculature, as mice lacking both 
receptors were more susceptible to hypoxia-induced pulmonary remodeling and 
the development of pulmonary arterial hypertension, characterized by declined 
peak flow velocity across the pulmonary valve, increased pulmonary arteriolar 
muscularization and wall thickness, as well as RV hypertrophy. Interestingly, 
while LPA1-/-2-/- mice showed exacerbated responses to hypoxia, we noted certain 
histological differences in lungs and hearts between these mice and WT controls at 
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baseline (normoxia). In normoxic WT mice, most of the small arterioles were 
non-muscularized in the lung. However, more than half of the small arterioles in 
LPA1-/-2-/- mice were muscularized (63% versus 18% of WT mice). The average 
thickness of pulmonary arteriolar wall was also significantly greater in normoxic 
LPA1-/-2-/- mice (6.0 ± 0.4 µm versus 4.6 ± 0.3 µm of WT, p<0.05). Both data 
indicated more remodeling in the pulmonary vasculature of LPA1-/-2-/- mice at 
baseline. In the heart, the RV to heart cross-section diameter ratio was also higher 
in LPA1-/-2-/- mice (0.16 ± 0.05 versus 0.11 ± 0.02 of WT), suggesting RV 
hypertrophy of LPA1-/-2-/- mice at baseline. Taken together, these data again 
suggest that mice lacking LPA1 and LPA2 receptors may develop pulmonary 
hypertension without hypoxia stimulation. 
In conclusion, our data provide novel evidences for LPA’s regulatory role in 
the pulmonary vasculature. By studying mouse models with elevated and reduced 
LPA levels, as well as impaired LPA signaling, our data suggest that signaling 
through LPA1 and 2 are necessary for pulmonary development as well as the 
maintenance of normal pulmonary vascular pressure.  
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Figure 4.1. Elevation of right ventricular systolic pressures (RVSP) and RV hypertrophy of aged
LPA1-/-2-/- mice.
A. RVSPOF 8-14 weeks old WT (N=6) and LPA1-/-2-/- (N=4) mice.
B. RVSP of over 45 weeks old WT (N=6), LPA1-/- (N=5), LPA2-/- (N=3), and LPA1-/-2-/- (N=4) mice.
Individual values (dots) and medium with 25 and 75 confidence intervals (box plots) are presented.
Data were analyzed by 2-way ANOVA. *P<0.05. NS: not statistically significant.
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Table 4.1. Peak flow velocity across the pulmonary valve of different age groups of LPA1-/-2-/-
mice.
Genotype Age (months) N PV velocity
WT 2-3 22 737.17 ± 75.62
WT 6-9 11 712.43  ± 99.62
LPA1-/-2-/- 2-3 18 666.92  ± 151.84
LPA1-/-2-/- 6-9 14 583.66  ± 48.12
Results are presented as mean ± SD in mm/sec. 
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Figure 4.2. Thickening of right ventricular free wall of LPA1-/-2-/- mice over 45 weeks old.
A. Representative pictures of heart cross-sections of age-matched WT and LPA1-/-2-/- mice. Hearts
were sectioned at the widest point transversely, and stained with H&E staining.
B. Quantification of RV free wall thickness to cross-section diameter ratio of aged mice. N=6 for
WT, N=4 for LPA1-/-, N=2 for LPA2-/-, and N=6 for LPA1-/-2-/- mice. *P<0.05.
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Figure 4.3. Cardiomyocyte hypertrophy of aged LPA1-/-2-/- mice.
A. Representative pictures of RV cardiomyocytes of age-matched WT and LPA1-/-2-/- mice. Hearts were
sectioned at the widest point transversely, and stained with PAS staining.
B. Quantification of cross-section area of individual cardiomyocytes in RV and LV walls of age-matched
WT (N=3) and LPA1-/-2-/- (N=4) mice.
C. Average numbers of cardiomyocyte nuclear numbers in each microscopic field in RV and LV walls of
age-matched WT (N=3) and LPA1-/-2-/- (N=4) mice.
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Figure 4.4. Normal arterial oxygen saturation, hematocrit , oxygen saturation and pulmonary valves of
LPA1-/-2-/- mice.
A. Arterial oxygen saturation percentage (O2 %) of WT (closed circle) and LPA1-/-2-/- (open circle) mice
from 8 to 32 weeks old.
B. Hematocrit (HCT %) of age-matched WT (n=8) and LPA1-/-2-/- (n=6) mice. Data are presented as
individual data and box plot. Individual values (dots) and medium with 25 and 75 confidence intervals
(box plots) are presented. Data were analyzed by 2-way ANOVA. NS: not statistically significant.
C. Hemaglobin concentration of age-matched WT (n=9) and LPA1-/-2-/- (n=6) mice. Data are presented
as individual data and box plot. Individual values (dots) and medium with 25 and 75 confidence
intervals (box plots) are presented. Data were analyzed by 2-way ANOVA. NS: not statistically
significant.
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Figure 4.5. Normal pulmonary vascular permeability and pulmonary valve of LPA1-/-2-/- mice.
A. Evans blue extracted from lung of age-matched WT (n=4) and LPA1-/-2-/- (n=4) mice. . Data are
presented as individual data and box plot. Individual values (dots) and medium with 25 and 75
confidence intervals (box plots) are presented. Data were analyzed by 2-way ANOVA. NS: not
statistically significant.
B. Representative pictures of heart sections at the level of pulmonary valves of WT and LPA1-/-2-/-
mice. Sections were stained with Masson’s trichrome staining. Pulmonary valves are indicated by
arrows.
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Figure 4.6. Lung histology of WT and LPA1-/-2-/- mice.
Lung histology of WT and LPA1-/-2-/- mice at different ages. From top to bottom: postnatal day 3 (P3),
postnatal day 7 (P7), 3 weeks old, and 12 weeks old, For 3 and 12 weeks old groups, lungs were
perfused by 4% paraformaldehyde through trachea, sectioned and stained with Masson’s trichrome
staining. For P3 and P7 groups, lungs were fixed, sectioned, and stained without perfusion.
Magnification: 200x.
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Figure 4.7. Increased perivascular elastin deposition in the lung of LPA1-/- 2-/- mice.
A. Quantitative RT-PCR analysis showing higher elastin expression level in lung of age-matched
LPA1-/-2-/- mice comparing to age-matched WT mice. N=2 for 3 weeks old group, and N=3 for 12
weeks old group. All results were presented as mean ± S.D. The expression level of WT is set as 1.
*P<0.05.
B. Quantification showing higher perivascular elastin content of LPA1-/-2-/- mice comparing to age-
matched WT mice. n=2 for 3 weeks old group, and N=4 for 12 weeks old group. *P<0.05.
C. Representative pictures of lung sections of 12 weeks old WT and LPA1-/-2-/- mice. Sections were
stained with elastin staining. Vessels are indicated by arrowheads.
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Table 4.2. Peak flow velocity across the pulmonary valve before and after 3 weeks of
exposure to normoxia and hypoxia.
N Before After
WT 6 633.99 ± 90.22 551.97 ± 154.02
LPA1-/-2-/- 5 607.66 ± 90.78 465.6   ± 149.21
Results are presented as mean ± SD. In mm/sec
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Figure 4.8. The response of mice deficient of LPA1 and 2 to hypoxia.
A. Percentages of muscularization of distal pulmonary arterioles in normoxic or hypoxic WT and LPA1-
/-2-/- mice. Lung sections were immunostained with a-smooth muscle actin and scored as described in
Materials and Methods. non= non muscularized vessels, partial= partially muscularized vessels, and
full= fully muscularized vessels. Increased numbers of fully muscularized pulmonary arterioles and less
non-muscularized arterioles of LPA1-/-2-/- mice, comparing to age-matched WT, are shown. Data are
presented as mean ± S.D from 4 mice/group and were analyzed by 2-way ANOVA. *P<0.05.
B. Thicker pulmonary arteriolar wall of LPA1-/-2-/- mice under both normoxic and hypoxic conditions,
comparing to age-matched WT. N=4 mice in each group, and data are presented as mean ± S.D.
*P<0.05.
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Figure 4.9. Right ventricular hypertrophy of LPA1-/-2-/- mice with 21 days of hypoxia.
A. Representative pictures of cross-sections of hearts of age-matched WT and LPA1-/-2-/- mice.
Hearts were sectioned at the widest point transversely, and stained with H&E staining.
B. Quantification showing higher RV free wall thickness to cross-section diameter ratio of LPA1-/-
2-/- mice comparing to age-matched WT controls in both normoxic and hypoxic conditions. N=5 in
each group.
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Figure 4.10. LPA receptors expression level in lung of LPA1-/-2-/- mice. Quantitative RT-PCR
analysis of LPA1-5 expression level in lung of age-matched WT (slashed bars) and LPA1-/-2-/-
(open bars) mice in normoxic and hypoxic conditions. All results were graphed from three
experiments and presented as mean ± S.D. The expression level of WT mice in normoxic
condition is set as 1. *P<0.05.
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Chapter 5 
Conclusions and future directions 
 
Mice with reduced and elevated LPA levels 
LPA is a bioactive lipid molecule present at physiologically relevant levels in 
plasma and serum 126. LPA has been shown to regulate the vasculature in various 
aspects. Acute administration of LPA triggers vessel constriction in rats and guinea 
pigs97  LPA had been proposed to contribute to phenotypic modulations such as 
proliferation and migration of culture vascular SMCs and appears to modulate 
arterial remodeling responses in carotid arteries of rodents 100.  LPA also has 
effects on endothelial cell function and endothelial barrier integrity 62,73,79. 
Therefore we proposed that LPA may be an important mediator in the pulmonary 
vasculature. 
The goal of this project was to determine if LPA signaling plays a role in 
regulation of pulmonary vasculature, specifically, the regulation of pulmonary 
vascular pressure. Our first strategy to evaluate a role for LPA in the pulmonary 
vasculature made use of mice with altered levels of circulating LPA. Mice 
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heterozygous of Enpp2, the gene encoding the major LPA producing enzyme 
autotaxin/lysoPLD, with ~half of circulating LPA, and transgenic mice 
overexpressing human Enpp2 with increased LPA level were used to determine 
their reactivity in the hypoxia-induced pulmonary hypertension. Enpp2+/- mice 
showed exaggerated responses to hypoxia with greater elevation in RVSP, 
reduction in peak flow velocity across the pulmonary valve, and increased 
remodeling of the pulmonary vasculature. These findings would be consistent with 
a normal role for LPA in preventing hypoxia-induced pulmonary vasoconstriction. 
Mice overexpressing human autotaxin/lysoPLD responded similarly to their WT 
controls, although they did display preserved peak flow velocity across the 
pulmonary valve after hypoxia, which might reflect mild protection from hypoxia. 
The phenotype of the Enpp2-Tg mice may be due to down-regulation of transgene 
expression that occurs during hypoxia, or due to the fact that physiological LPA 
levels are sufficient to exert the protective effect and further increases may 
provide no additional benefit. Together, our data suggest that the maintenance of 
local or circulating LPA levels may offset the pulmonary vascular changes that are 
elicited by hypoxia. An alternate explanation is that mice with circulating defects 
in LPA levels develop compensatory responses that make them more prone to 
hypoxia-induced changes.  
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Mice deficient of LPA receptors 1 and 2 
    Having established that LPA regulates pulmonary vascular pressure, we 
investigated potential receptor(s) involved. Given the high expression levels of 
LPA1 and LPA2 in vascular SMCs and endothelial cells, we sought to determine 
whether LPA1 and LPA2 participate in the regulatory effect. We found that mice 
lacking both LPA receptors 1 and 2 (LPA1-/-2-/- mice) developed spontaneous 
pulmonary hypertension with age, as evidenced by an elevation in RVSP in the 
absence of pulmonary valve abnormalities, a decline in peak flow velocity across 
the pulmonary valve, development of RV hypertrophy, and histological evidence 
of pulmonary vascular remodeling. While no significant difference in RVSP was 
found that in young adult LPA1-/-2-/- and WT controls, the RVSP of aged 
LPA1-/-2-/- mice was significantly higher than age-matched WT mice. Aged 
LPA1-/- mice may display a slightly higher RVSP than WT controls, while LPA2-/- 
mice had normal RVSP, indicating lack of LPA1 may have partial effect on the 
age-dependent development of pulmonary hypertension. Nevertheless, neither 
LPA1-/- and LPA2-/- mice displayed the significant elevation of RVSP observed in 
the LPA1-/-2-/- mice, suggesting redundant signaling pathways between these two 
receptors, and that lack of only one receptor is not sufficient to cause the 
pronounced phenotype observed in the absence of both receptors. To investigate 
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receptor dose-dependent effects in more detail, LPA1+/-2-/- and LPA1-/-2+/- mice 
could be evaluated to determine. It would be interesting to know whether any of 
these strains spontaneously develop certain degree of pulmonary hypertension as 
did the LPA1-/-2-/- mice, or they would be rather similar to the single knockout 
mice.  
    I excluded common causes of secondary pulmonary hypertension, such as 
hypoxia, pulmonary valve stenosis, obstruction in the main pulmonary vasculature, 
and thromboembolism, as the reason of elevated pulmonary pressure in LPA1-/-2-/- 
mice. The integrity of endothelial layers in the lung was also examined by 
endothelial permeability assay. No significant increase in pulmonary endothelial 
permeability was found in LPA1-/-2-/- mice. Tager and colleagues have recently 
reported LPA1-deficient mice are protected from bleomycin-induced lung injury, 
with reduced pulmonary endothelial permeability and fibrosis after the challenge 
109,123
. It would be worthwhile evaluating the pulmonary permeability and fibrosis 
of LPA1-/-2-/- mice in the lung injury model. Interestingly, Tager et al. stated no 
significant differences in the numbers of total leukocytes, macrophages, or 
neutrophils in the BAL of LPA1-/- mice, which is similar to our observations that no 
sign of increase in inflammatory cells infiltration in lung tissues of LPA1-/-2-/- mice. 
I observed enlarged alveolar spaces in the lung of LPA1-/-2-/- mice. I therefore 
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sought to determine whether the lung development was affected by lack of LPA 1 
and 2. Alveolar enlargement occurred in LPA1-/-2-/- mice as early as 3 and 12 
weeks of age. No obvious differences were seen at postnatal day 3 and 7, 
suggesting the impairment of pulmonary development likely occurred between 
postnatal day 7 and 21, when alveolar septation occurs. The percentages of 
muscularized arterioles were greater in both 3 and 12 weeks old LPA1-/-2-/- mice, 
comparing to age-matched WT controls, suggesting the vascular remodeling was 
evident as early as 3 weeks of age. The fact that pulmonary histology of LPA1-/- 
and LPA2-/- mice appears to be normal without alveolar enlargement again 
suggests the redundancy of LPA1 and LPA2 in the regulation of pulmonary 
vasculature (data not shown).  
Alveolarization and angiogenesis tightly associate and coordinate with each 
other during lung development, and inhibition of angiogenesis would result in 
impaired alveolarization 8. The expression levels of angiogenetic markers Tie-1, 
VEGF, and VEGFRII in the lung tissues were similar among genotypes and 
normoxia/hypoxia treatments (data not shown). However, our result could be 
attributed to dilution of vascular cells by other cells types, such as pneumocytes, 
in the lung. Therefore we could not conclude that angiogenesis is not affected in 
the lung of LPA1-/-2-/- mice without further confirmation.   
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Impaired alveolarization in newborns and increased pulmonary pressure later 
in life are the two main problems spontaneously developed in the lung of 
LPA1-/-2-/- mice. Multiple reports have linked alveolarization with pulmonary 
hypertension. Dexamethasone treatment on neonatal rats reduces alveolarization 
and pulmonary artery counts. When challenged with hypoxia, rats received 
dexamethasone in the neonatal period displayed significant higher RVSP and RV 
mass 142. Fetal lambs undergone surgery of ductus arteriosus constriction to induce 
pulmonary hypertension showed reduced alveolarization and small pulmonary 
artery density 143. These examples suggest mutual regulations between pulmonary 
pressure and development. Furthermore, the pathways regulating alveolarization 
and pulmonary pressure may be highly associated. Lacking LPA signaling may 
contribute to both impaired alveolarization and pulmonary hypertension in mice, 
or it could have crucial effect on one event, which with time affecting the other 
one.        
Gene expression and perivascular levels of elastin, one of the major ECM 
components in the lung, were up-regulated in lungs of 3 and 12 weeks old 
LPA1-/-2-/- mice. The increase of perivascular elastin in LPA1-/-2-/- mice may 
reflect alterations in pulmonary arterial pressure and/or abnormal vascular 
development in the LPA1-/-2-/- mice.  
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LPA1-/-2-/- mice showed exacerbated responses to hypoxia with greater 
decline in peak flow velocity across the pulmonary valve, pulmonary vascular 
remodeling, as well as RV hypertrophy. Interestingly, we noted greater 
muscularization percentages and vascular wall thickness in the lung of LPA1-/-2-/- 
mice compared to WT mice in the normoxic group. In the heart, the RV to heart 
cross-section diameter ratio was also greater in LPA1-/-2-/- mice. Both results 
indicate the development of spontaneous pulmonary remodeling and RV 
hypertrophy in young adult LPA1-/-2-/- mice at baseline. These data were in 
accordance with the spontaneous development of pulmonary hypertension in 
LPA1-/-2-/- mice over time.  
In conclusion, our data provide novel evidences for the regulatory role of 
LPA in the pulmonary vasculature. By studying mouse models with elevated and 
reduced LPA levels, as well as mice with deficiencies in LPA receptors, our data 
suggest that signaling through LPA1 and 2 are necessary for pulmonary 
development as well as the maintenance of normal pulmonary vascular pressure.  
Although no other reports have suggested the role of LPA in regulating 
pulmonary pressure, multiple studies have shown the regulatory effect of LPA in 
other vascular beds. For example, intravenous injection of LPA elevates arterial 
blood pressure in rats 97 and local application causes cerebral vasoconstriction in 
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pigs 98. Moreover, local infusion of LPA in the rat common carotid artery induces 
vascular remodeling by stimulating neointimal formation 99. A similar response 
was observed in mice 77. Interestingly, these studies all indicate that LPA acts to 
increase blood pressure, which contradicts with our data that LPA protects against 
pulmonary pressure elevation. We wonder whether the protective effect we 
observed was due to compensation to off-set lack of LPA signaling. However, 
pulmonary vasculature is unique in many aspects to vascular beds in the systemic 
circulation, where other studies took place in. In addition, the long-term loss of 
LPA signaling in our models may result in different responses, such as 
compensatory mechanisms in vivo, whereas other studies monitored short-term 
effects by administration of exogenous LPA. To determine the role of LPA in 
pulmonary vascular reactivity, we will perfuse isolated mouse lungs with LPA at a 
constant physiological-relevant flow rate, and measure the real-time pressure to 
see whether acute infusion of LPA mediates pulmonary vascular pressure change. 
Preliminary lung perfusion experiment with physiological-relevant concentration 
of LPA failed to increase pulmonary pressure under conditions where vasoactive 
compound did, suggesting that there may be different effects of LPA on systemic 
and pulmonary vasculature in mice. Additional experiments may be performed to 
determine if LPA can block the increase in pulmonary pressure elicited by 
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vasoconstrictors.       
 
Proposed molecular mechanisms 
As mentioned in chapter 1, pulmonary arterial hypertension develops as a 
consequence of an imbalance between vasodilators and vasoconstrictors 22,27,29. To 
explore how LPA signaling maintains the pulmonary pressure, the integrity of three 
major vasoconstricting and vadodilatory pathways in the pulmonary vasculature, 
nitric oxide, endothelin, and prostacyclin, will be examined.  
 
Nitric oxide 
    LPA has been shown to act as a potent activator of eNOS, the major NO 
producing enzyme in the pulmonary vasculature. LPA activates eNOS and increase 
NO production in a receptor-dependent manner in cultured endothelial cells 113,144. 
In the animal model, eNOS knockout mice were hyperresponsive to hypoxia and 
developed exaggerated elevations in RVSP and have a higher incidence to develop 
RV hypertrophy 37, 38. On the other hand, mice overexpressing eNOS are protected 
from hypoxia-induced pulmonary hypertension 36. The responses of Enpp2+/- and 
Enpp2-Tg mice phenocopied eNOS-/- and eNOS-Tg mice in hypoxia exposure.  
We hypothesized that the deficiency of circulating LPA level or lack of LPA1 and 2 
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would result in insufficient eNOS activation in response to hypoxia-induced 
vasoconstriction, and hence lead to pulmonary hypertension. We measured 
expression levels of mediators in the NO pathways, Vegfr2, Pde5a, and Nos3 by 
quantitative RT-PCR. Our preliminary data show that the expression levels of all 
three mediators were normal in lungs of Enpp2+/-, Enpp2-Tg, and LPA1-/-2-/- mice.  
Exposure to hypoxia produced a 30 – 40% increase in Vegfr2 and Pde5a expression 
and an approximately 50% decline in Nos3 expression in WT mice. Similar changes 
occurred in Enpp2+/-, Enpp2-Tg, and LPA1-/-2-/- mice with hypoxia. Therefore there 
was no difference in the expression patterns among genotypes and treatments. In 
addition to the expression pattern, our preliminary data showed that the content of 
total nitrate/nitrite, the metabolites of NO, was normal in the plasma of LPA1-/-2-/- 
mice. However, since LPA has been shown to stimulate eNOS activation without 
affecting eNOS protein level 113, we will perform eNOS activity assays, such as 
quantification of the phosphorylated form of eNOS in western blotting to determine 
whether eNOS signaling is inhibited in Enpp2+/- and/or LPA1-/-2-/- mice.          
 
Endothelin 
LPA has been reported to increase endothelin expression and production in 
several studies. The expression level of ET-1 (Edn1), and the secretion of ET-1 are 
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both increased in LPA treated rat aortic endothelial cells 145. LPA also up-regulates 
the production of ET-1 in pig cerebral microvascular endothelial cells 146,147. We 
therefore sought to examine the expression levels of major mediators in the 
endothelin pathway. Our preliminary data show that the expression  levels of Edn1 
and vasoconstrictive the ETA receptor (Ednra) were constantly greater in LPA1-/-2-/- 
mice than age-matched WT controls at various ages (P7 and 3 and 12 weeks old). 
Hypoxia reduced gene expression of the ETB receptor (Ednrb), the vasodilatory and 
clearing receptor, in WT mice, an effect that was exacerbated in Enpp2+/- and 
LPA1-/-2-/- mice. A recent paper reporting endothelium-specific ETB receptor 
knockout mice are susceptible to hypoxia with elevated RVSP and increase in RV 
mass as well as remodeled pulmonary arterioles, suggesting the requirement of ETB 
in limiting the development of pulmonary hypertension in response to hypoxia 148. 
Our preliminary data support the model that the vasoconstrictive endothelin 
pathway is up-regulated due to reduction in LPA level or deficiency of LPA1 and 
LPA2. To confirm that the difference in gene expression is reflected in peptide 
levels, ELISA assays quantifying pulmonary ET-1 will be performed.  
 
Prostacyclin 
    We will also examine the gene expression of mediators in the prostacyclin 
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pathway, not only because prostacyclin is a potent vasodilator, but also because it 
inhibits the production of ET-1 149. In addition, LPA has been reported to promote 
prostacyclin secretion 150. Quantification of the metabolites of prostacyclin in 
mouse urine will be performed by mass spectrometry to see whether the 
prostacyclin pathway is affected with increased or decreased LPA signaling. 
     
In sum, our data provide novel evidences for LPA’s regulatory role in the 
pulmonary vasculature. By studying mouse models with elevated and reduced 
LPA levels, as well as deficiency of LPA receptors, our data suggest that signaling 
through LPA1 and 2 are necessary for pulmonary development as well as the 
maintenance of normal pulmonary vascular pressure.  
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